var title_f18_12_18624="Algorithm for nonhealing pressure ulcer management";
var content_f18_12_18624=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Algorithm for nonhealing pressure ulcer management",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 668px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_12_18624=[""].join("\n");
var outline_f18_12_18624=null;
var title_f18_12_18625="Algorithm for management of neonatal polycythemia";
var content_f18_12_18625=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F85758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F85758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 612px\">",
"   <div class=\"ttl\">",
"    Algorithm for management of neonatal polycythemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 592px; height: 661px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The management approaches outlined in this algorithm are based primarily upon expert opinion. There is insufficient evidence to fully assess the efficacy or safety of partial exchange transfusion (PET), or the clinical indications for this procedure.",
"    <div class=\"footnotes\">",
"     * Refer to table on Causes of neonatal polycythemia.",
"     <br/>",
"     &Delta; Observation consists of: monitor intake, weight, and urine output; follow up blood glucose as indicated based on initial results; monitor for symptoms.",
"     <br/>",
"     <span style=\"color: #0000ff;\">",
"      <span class=\"lozenge\">",
"       &loz;",
"      </span>",
"      Preferred pathways in the authors' institution.",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_12_18625=[""].join("\n");
var outline_f18_12_18625=null;
var title_f18_12_18626="Nail sarcoidosis";
var content_f18_12_18626=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sarcoidosis involving the nail",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sarcoidal dactylitis. Swelling and deformity of all fingers are present. Some fingers demonstrate erythema and swelling of the nail folds and beds. Marked onychodystrophy is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_12_18626=[""].join("\n");
var outline_f18_12_18626=null;
var title_f18_12_18627="Apical 4 chamber color flow Doppler MR II";
var content_f18_12_18627=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Apical four chamber view showing color flow Doppler of mitral regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 460px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A is an apical four chamber view in systole showing color jets of mild mitral regurgitation (MR) and mild tricuspid regurgitation (TR). The jets are central and do not penetrate the left atrium (LA) on right atrium (RA) beyond the mid cavity. Panel B shows an apical four chamber view in patients with severe MR; the arrows outline the course of a jet during systole that adheres to and follows the contour of the LA. Such wall hugging jets are typical of severe regurgitation. Since their area is smaller than central jets, the use of wall hugging jet area as a sign of MR severity is not recommended.",
"    <div class=\"footnotes\">",
"     LV: left ventricle; RA: right atrium; RV: right ventricle.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_12_18627=[""].join("\n");
var outline_f18_12_18627=null;
var title_f18_12_18628="Dyphylline and guaifenesin: Patient drug information";
var content_f18_12_18628=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dyphylline and guaifenesin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/24/30083?source=see_link\">",
"     see \"Dyphylline and guaifenesin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F4110881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Difil-G&reg; 400",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691768",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat breathing problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dyphylline, guaifenesin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an overactive thyroid, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697167",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an ulcer in the stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698996",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Peak flow measurement low.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12427 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-AA596B28AF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_12_18628=[""].join("\n");
var outline_f18_12_18628=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4110881\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018344\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018343\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018348\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018349\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018351\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018346\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018347\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018352\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018353\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/24/30083?source=related_link\">",
"      Dyphylline and guaifenesin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_12_18629="Atrial tachycardia tutorial";
var content_f18_12_18629=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1046px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atrial tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 231px; height: 96px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atrial tachycardia is a supraventricular tachyarrhythmia that has a rate of 140 to 220 beats per minute. The QRS complexes occur at regular intervals (ie, there is constant RR cycle length), the P waves have a uniform morphology, and the PR interval is constant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_12_18629=[""].join("\n");
var outline_f18_12_18629=null;
var title_f18_12_18630="CT cystogram bladder rupture intraperitoneal";
var content_f18_12_18630=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT cystogram of intraperitoneal bladder rupture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This CT cystogram reveals an intraperitoneal bladder rupture. Contrast outlines several loops of bowel (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael S Runyon, MD, FAAEM.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_12_18630=[""].join("\n");
var outline_f18_12_18630=null;
var title_f18_12_18631="Abnormally short frenulum";
var content_f18_12_18631=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74275%7EPEDS%2F60685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74275%7EPEDS%2F60685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abnormally short frenulum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Abnormally short frenulum, inserting at or near the tip of the tongue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ankyloglossia in a newborn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Abnormally short frenulum, inserting at the tip of the tongue in a neonate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_12_18631=[""].join("\n");
var outline_f18_12_18631=null;
var title_f18_12_18632="Peritoneal dialysis solutions";
var content_f18_12_18632=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Peritoneal dialysis solutions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/12/18632/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/12/18632/contributors\">",
"     Muhammad Alam, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/12/18632/contributors\">",
"     Michelle W Krause, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/12/18632/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/12/18632/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/12/18632/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/12/18632/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/12/18632/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the ancient Egyptians were the first to describe the peritoneal cavity in approximately 3000 BC, the concept of peritoneal dialysis is relatively new. In the late 19th century, Wegner, a German investigator, was the first to use peritoneal solutions in animals; he reported that hypertonic solutions increased in volume when injected into the peritoneal cavity. Additional investigations found that hypertonic solutions increased and hypotonic solutions decreased peritoneal fluid volume [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various different investigators subsequently evaluated the efficacy of treating uremia by instilling fluids into the peritoneal cavity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gantar instilled saline solution in the peritoneal cavity of uremic guinea pigs, and subsequently treated a uremic woman with peritoneal dialysis (PD) solution containing saline.",
"     </li>",
"     <li>",
"      Heusser added dextrose to the PD solution to improve ultrafiltration.",
"     </li>",
"     <li>",
"      In 1938, Rhoads added lactate to the PD fluid to correct acidosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several peritoneal dialysis solutions were subsequently used in the management of uremic patients. Besides saline, they included glucose solutions, gelatin, xylitol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    , glucose polymer (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    ), amino acids, and many other agents [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Dan Baxter company made the first commercial dialysis solution available in 1959. Subsequently, there has been very little change in the basic composition of these solutions. A review of peritoneal dialysis solutions will be presented here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IDEAL SOLUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritoneal dialysis solutions consist of water, osmotic agents, electrolytes and minerals and are sometimes fortified with different substances. An ideal solution should [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Have a sustained and a predictable solute clearance with minimal absorption of the osmotic agents",
"     </li>",
"     <li>",
"      Provide deficient electrolytes and nutrients, if required",
"     </li>",
"     <li>",
"      Correct acid base problems without interacting with other solutes in the peritoneal dialysis fluid",
"     </li>",
"     <li>",
"      Be free of and inhibit the growth of pyrogens and microorganisms",
"     </li>",
"     <li>",
"      Be free of toxic metals",
"     </li>",
"     <li>",
"      Be inert to the peritoneum",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CONSTITUENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritoneal dialysis solutions have not significantly changed since they were made available commercially in 1959. The earlier solutions were packaged in glass bottles, but they are currently available in several sizes of collapsible plastic bags. The constituents can be broadly divided into osmotic agents, buffers, and electrolytes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Osmotic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid removal is essential in dialysis patients. Osmotic agents, being hyperosmolar, allow net water removal by altering the osmotic pressure gradient between the peritoneal dialysis solution and plasma water. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/63/33784?source=see_link\">",
"     \"Mechanisms of solute clearance and ultrafiltration in peritoneal dialysis\"",
"    </a>",
"    .) The initial PD solutions were saline solutions, but since the 1940s,",
"    <strong>",
"     dextrose",
"    </strong>",
"    has been commonly used as the osmotic agent. Several investigators have attempted to use other osmotic agents in PD solutions, but have been unable to show any better overall performance.",
"   </p>",
"   <p>",
"    Properties of an ideal osmotic agent include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Metabolized easily with non-toxic degradation products",
"     </li>",
"     <li>",
"      Poorly absorbed",
"     </li>",
"     <li>",
"      Inert and non-toxic to the peritoneal membrane",
"     </li>",
"     <li>",
"      Inexpensive",
"     </li>",
"     <li>",
"      Effective osmotic agent at low concentration",
"     </li>",
"     <li>",
"      No metabolic consequences of absorption",
"     </li>",
"     <li>",
"      Must be of nutritional value, if absorbed",
"     </li>",
"     <li>",
"      Not difficult to manufacture",
"     </li>",
"     <li>",
"      Should not inhibit peritoneal defenses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The two major types of osmotic agents that are currently used in peritoneal dialysis are generally classified as agents with high or low molecular weight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     High molecular weight agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;High molecular weight agents, such as glucose polymers, polypeptides,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    , gelatin and polycations, range in weight from 20,000 to 350,000 DA. With these agents, a high concentration is required to produce an osmolar gradient, which could lead to hyperviscosity, thereby affecting dialysis inflow and outflow.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucose polymer-containing solutions (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"       icodextrin",
"      </a>",
"      ) &mdash; Glucose polymers (eg, icodextrin) are mixtures of",
"      <span class=\"nowrap\">",
"       oligo/polysaccharides",
"      </span>",
"      of variable chain lengths. Initially, low molecular weight",
"      <span class=\"nowrap\">",
"       oligo/polysaccharides",
"      </span>",
"      with weights of approximately 900 DA were tried with limited success. Larger molecules with weights of 20,000 DA have been introduced in Europe [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/8\">",
"       8",
"      </a>",
"      ]. Icodextrin dialysate (Extraneal&trade;) is the major glucose polymer utilized in peritoneal dialysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Glucose polymers were introduced to replace glucose containing solutions, by offering the possible advantages of decreased absorption of solute and increased ultrafiltration for a longer period of time.",
"   </p>",
"   <p>",
"    The use of a glucose polymer as an osmotic agent is particularly appealing as a substitute for glucose solutions, particularly in diabetics, in those who require long dwell, and in patients whose ultrafiltration capacity may need to be enhanced [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. The reduced carbohydrate load also may provide some long-term metabolic advantage.",
"   </p>",
"   <p>",
"    The most commonly used glucose polymer is a 7.5 percent solution. The blood concentrations of maltose, maltotriose, and other",
"    <span class=\"nowrap\">",
"     oligo/polysaccharides",
"    </span>",
"    have been shown to increase with these agents, possibly resulting in adverse reactions. Several studies, for example, have reported a relatively high incidence of cutaneous reactions (approximately 15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reported incidence of culture-negative peritonitis with glucose polymer solutions ranges from 9 to nearly 50 percent. This is thought to be due to contamination of some batches with a bacterial wall breakdown product, peptidoglycan. The manufacturer subsequently had a voluntary recall of the suspect batches of dialysate, with a resultant decrease in incidence of the peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=see_link\">",
"     \"Microbiology and therapy of peritonitis in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    and maltose can interfere with or cause falsely elevated glucose results, possibly leading to inappropriate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Thus, the labeling for Extraneal includes a warning that \"blood glucose monitoring must be done with a glucose-specific method (monitor and test strips) to avoid interference by maltose.\"",
"   </p>",
"   <p>",
"    In one retrospective study, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    was associated with a lower risk of technique failure related to non-compliance and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/18\">",
"     18",
"    </a>",
"    ]. These results need to be confirmed in a randomized trial.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polypeptides &mdash; Polypeptides may be used as osmotic agents by the hydrolysis of a 5 percent solution of a milk protein with the enzymes trypsin and chymotrypsin [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/19\">",
"       19",
"      </a>",
"      ]. Compared to a 2.5 percent glucose solution, this polypeptide solution yielded twice the ultrafiltrate volume after one hour of dwell. Furthermore, only 3 percent of the peptide was absorbed from the solution. In another study, 10 stable CAPD patients received either 1 percent peptide with 1.36 percent glucose (osmolality of 381",
"      <span class=\"nowrap\">",
"       mosmol/kg)",
"      </span>",
"      or 2.27 percent glucose (osmolality of 404",
"      <span class=\"nowrap\">",
"       mosmol/kg)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/20\">",
"       20",
"      </a>",
"      ]. The peptide solution was well tolerated, resulting in a similar clearance as the 2.27 percent glucose solution. Furthermore, there were no irritant effects of the peptide solution on the peritoneum and the plasma amino acid profile was similar in both groups. Thus, short chain polypeptides were absorbed less than glucose and their ultrafiltration capacity was similar to 2.27 percent glucose. However, long-term studies are needed to evaluate the effects of peptide on the nutritional status of peritoneal dialysis patients.",
"     </li>",
"     <li>",
"      Dextrans &mdash; Neutral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"       dextran",
"      </a>",
"      had been tried as an osmotic agent since the 1960s. Initially, 6 percent Dextran in saline was utilized, but this concentration was unable to achieve good ultrafiltration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 10 percent solution provided good ultrafiltration, but 40 to 60 percent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    was absorbed over a six-hour dwell time [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/21\">",
"     21",
"    </a>",
"    ]. Accumulation of dextran in the body can result in blockage of the reticuloendothelial system; thus, it is",
"    <strong>",
"     not",
"    </strong>",
"    considered a suitable alternative for peritoneal dialysis solutions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Low molecular weight agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low molecular weight agents, such as dextrose (eg, glucose containing solutions), amino acids, xylitol, and glycerol, have weights of 90 to 200 DA. Among these agents, dextrose is the most commonly used.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucose-containing solutions &mdash; Glucose is the most commonly utilized osmotic agent in peritoneal dialysis. It comes in three different dextrose monohydrate concentrations: 1.5, 2.5, and 4.25 percent (see below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Glucose is not the ideal osmotic agent because it is easily absorbed, leading to short-lived ultrafiltration. Its absorption can also lead to several metabolic complications, such as hyperinsulinemia, hyperglycemia, hyperlipidemia, and weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/22\">",
"     22",
"    </a>",
"    ]. Furthermore, the high glucose concentration, low pH, glucose degradation products (GPDs) of these solutions can affect peritoneal host defense mechanisms by inhibiting phagocytosis and bactericidal activity due in part to overall bioincompatibility [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neutral pH, low glucose degradation product or &ldquo;biocompatible&rdquo; peritoneal dialysis solutions have been developed in an attempt to decrease the number of glucose degradation products of dialysis solutions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The use of such solutions may preserve daily urine volume, though not necessarily residual renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Residual renal function in this setting is defined as solute (eg, urea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    creatinine) clearance.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One multicenter randomized trial compared biocompatible dialysate with conventional dialysate among 185 PD patients with residual renal function [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/26\">",
"       26",
"      </a>",
"      ]. At two years there was no difference in the rate of decline in renal function. However the use of the biocompatible solution associated with a decreased risk of anuria (adjusted hazard ratio 0.36, 95% CI 0.13-0.96) and a decreased rate of peritonitis (0.30 versus 0.49 episodes per patient-year) compared with conventional dialysate.",
"     </li>",
"     <li>",
"      A randomized open-label study compared three biocompatible dialysate solutions to conventional dialysate solution among 150 incident CAPD patients [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/27\">",
"       27",
"      </a>",
"      ]. At 12 months, patients who used biocompatible solutions had better preservation of daily urine volume compared with those who used a conventional dialysate solution (959 versus 798",
"      <span class=\"nowrap\">",
"       mL/day)",
"      </span>",
"      but there was no difference between groups in the rate of decline of residual renal function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One retrospective study of over 2000 patients has suggested a survival benefit associated with a neutral pH low GPD solution [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/25\">",
"     25",
"    </a>",
"    ]. Randomized, prospective studies are required to accurately determine the possible survival benefits associated with this solution [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main advantage of dextrose is that it is cheap, safe, and easily available. Furthermore, nephrologists are comfortable using dextrose solutions as they have been in the market for a long time. To date, no other osmotic agent has proven superior to dextrose-containing solutions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Amino acid-containing solutions &mdash; Nutrition is being increasingly recognized as an important predictor of outcome in dialysis patients [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14519?source=see_link\">",
"       \"Nutritional status and protein intake in continuous peritoneal dialysis\"",
"      </a>",
"      .) Malnutrition is common in peritoneal dialysis patients [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/31\">",
"       31",
"      </a>",
"      ] and has been associated with higher mortality and higher hospitalization rates. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link\">",
"       \"Patient survival and maintenance dialysis\"",
"      </a>",
"      .) Whereas several factors are responsible for the low albumin levels in dialysis patients, peritoneal dialysis patients tend to lose significant amounts of protein in the dialysate. It is estimated that up to 15 gm of protein and 2 to 4 grams of amino acids per day may be lost [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/32-34\">",
"       32-34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Amino acid containing peritoneal dialysis solutions have therefore been utilized to possibly improve nutritional status in peritoneal dialysis patients. The rationale behind this approach was that the absorbed amino acids from the peritoneal dialysis solution might help contribute to protein synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, early experiences with amino acid solutions were not very successful, with little to no nutritional benefit evident in studied patients. One explanation for the lack of benefit is that earlier amino acid solutions were not well designed for peritoneal dialysis. By comparison, subsequent studies found that 1.1 percent amino acid solutions are as effective an osmotic agent as 1.36 percent dextrose solutions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/36\">",
"     36",
"    </a>",
"    ]. Such studies have also shown optimal utility when amino acids were administered with a non-protein energy source.",
"   </p>",
"   <p>",
"    The amino acid solution used in these studies was a 1.1 percent solution of a combination of essential amino acids and some non-essential amino acids (Nutrineal: Baxter Health Care). The pH of this solution is 6.7 and osmolality is 365",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/37\">",
"     37",
"    </a>",
"    ]. In various studies, this solution has been shown to improve the nutritional status of dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/38\">",
"     38",
"    </a>",
"    ]. The common side effects include worsening of acidosis and a rise in BUN.",
"   </p>",
"   <p>",
"    The following guidelines should be considered when prescribing amino acid peritoneal dialysis solutions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They are indicated for use only in malnourished or diabetic patients,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      those with recurrent peritonitis.",
"     </li>",
"     <li>",
"      A 1.1 percent amino acid solution consisting of predominantly essential amino acids (required by dialysis patients) should be used.",
"     </li>",
"     <li>",
"      Sufficient concurrent alternative caloric intake should be guaranteed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9274?source=see_link\">",
"     \"Pathogenesis and treatment of malnutrition in maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Xylitol-containing solution &mdash; Xylitol has been tried as an osmotic agent in diabetic patients. A preliminary study found that its use helped decrease metabolic complications of diabetes as well as blood glucose levels [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/40\">",
"       40",
"      </a>",
"      ]. However, it is not currently used because of several potentially serious side effects, including lactic acidosis, hyperuricemia, carcinogenicity, and deteriorating liver function.",
"     </li>",
"     <li>",
"      Glycerol-containing solution &mdash; Glycerol gained interest as an osmotic agent because of its smaller molecular weight, relatively high osmolality per unit mass, and a higher pH than glucose solutions. It was therefore initially proposed as the alternative solution in diabetic patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, because of rapid diffusion into blood, it produces less ultrafiltration than glucose. In addition, long term trials found that the insulin requirement was not significantly different after three to four months; furthermore, its regular use may lead to accumulation of glycerol, and cause hyperosmolality of the plasma and hypertriglyceridemia. Thus, glycerol solutions have a limited role in diabetic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Buffers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three different agents have been used as buffers to control acidosis in peritoneal dialysis patients. These are acetate, lactate, and bicarbonate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Lactate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lactate is a commonly used agent to control acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/24,43\">",
"     24,43",
"    </a>",
"    ]. It is sometimes associated with inflow pain. Furthermore, occasional excessive absorption of lactate may lead to encephalopathy. Nonetheless, a lactate buffer is generally quite safe. It is commercially available in concentrations of 35",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    and 40",
"    <span class=\"nowrap\">",
"     mmol/L.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Acetate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acetate",
"    controls the metabolic acidosis of chronic uremia as well as lactate; however, the major drawback is that acetate frequently causes pain during inflow, as well as sclerosing peritonitis, the latter leading to poor ultrafiltration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Bicarbonate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with other buffers, bicarbonate controls acidosis in a more physiologic fashion. However, it is not compatible with calcium and magnesium containing solutions, particularly if stored for a prolonged period. This problem can be circumvented by using two separate bags (one containing bicarbonate and the other containing calcium and magnesium), which mix together at the time of infusing the solutions.",
"   </p>",
"   <p>",
"    However, this procedure was cumbersome for patients and did not gain popularity. Different concentrations of bicarbonate have been mixed with lactate, with variable results [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/44-50\">",
"     44-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Electrolytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commercially available solutions contain sodium, magnesium, calcium, and chloride. In some settings, minerals like iron pyrophosphate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/51\">",
"     51",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/52\">",
"     52",
"    </a>",
"    ] have also been added to the peritoneal dialysis solutions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=see_link\">",
"     \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=see_link\">",
"     \"Use of iron preparations in hemodialysis patients\"",
"    </a>",
"    .) In addition, potassium can be added to the peritoneal dialysis solution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sodium concentration in peritoneal dialysis solutions varies from 130 to 137",
"    <span class=\"nowrap\">",
"     mmol/L.",
"    </span>",
"    In North America, the sodium concentration of the dialysate is principally 132",
"    <span class=\"nowrap\">",
"     mmol/L.",
"    </span>",
"    Since fluid removal with peritoneal dialysis is mainly by convection, water removal from the plasma exceeds sodium removal, thereby possibly leading to hypernatremia. Thus, the relatively low sodium concentration in the PD fluid helps offset the predilection for hypernatremia. Nomograms are available to predict net sodium removal, adjusted for glucose concentration of the solution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 1970s, the most commonly used calcium concentration in peritoneal dialysis solutions was 1.75",
"    <span class=\"nowrap\">",
"     mmol/L.",
"    </span>",
"    At present, the optimal peritoneal dialysis calcium concentration is unclear. Hypercalcemia is common in patients using 1.75",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    of calcium in the dialysate, which is due to the concurrent administration of calcium-containing phosphate binders and vitamin D analogues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, an increasing number of centers are now using low calcium concentrations in the dialysate, which can help in the treatment of hyperphosphatemia with calcium-containing phosphate binders. Studies have shown that lower dialysate calcium (1.25",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    seems to be safe in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/53\">",
"     53",
"    </a>",
"    ]. However, hypocalcemia may develop in some patients, particularly in those with poor compliance with calcium containing phosphorus binders [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Magnesium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypermagnesemia is a frequent occurrence in peritoneal dialysis patients. Currently available PD solutions contain magnesium at concentrations of 0.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    to 1.5",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    In most studies, the use of 1.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    of magnesium in the dialysate solution resulted in hypermagnesemia. Since persistently elevated magnesium levels may cause bone disease, the 0.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    concentration is therefore more commonly used to optimize the serum magnesium concentration. A zero dialysate magnesium concentration has also been attempted to allow the use of oral magnesium salt as an additional phosphate binder [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Potassium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potassium is usually not added in the commercial dialysate; potassium concentration in commercially available dialysate can vary from 0 to 2",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    Zero potassium dialysate tends to maintain serum potassium around 4",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    Interestingly, 10 to 36 percent of PD patients develop hypokalemia, which could be corrected by adding 1 to 4",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    of potassium to the dialysate as required. However, a strongly preferred method is to supplement potassium orally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     AVAILABLE DEXTROSE BASED SOLUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritoneal dialysis solutions are available in different volumes, dextrose concentrations, and formulations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritoneal dialysis solutions are commonly available in 1 liter, 2 liter, 2.5 liter, 3 liter, 5 liter, and 6 liter bags. In the United States, these bags were initially available in glass bottles, but they are currently commercially packaged in collapsible plastic bags.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Dextrose concentrations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three different dextrose concentrations are currently available: 1.5 percent, 2.5 percent, and 4.25 percent dextrose solutions. The osmolality of these solutions is 346, 396, and 485 respectively. The adequate management of volume status in a peritoneal dialysis patient involves alternating the different concentrations of dextrose containing solutions to achieve dry weight and blood pressure control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently, different peritoneal dialysis formulations are commonly used and are available with different concentrations of dextrose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Standard solution",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard solution contains 132",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    of sodium along with 3.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    calcium, 1.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    magnesium, 35",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    lactate, and 102",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    of chloride (",
"    <a class=\"graphic graphic_table graphicRef78759 \" href=\"UTD.htm?6/0/6155\">",
"     table 1",
"    </a>",
"    ). Although this formulation is commonly referred to as the standard solution, this is not necessarily the most commonly prescribed or the best available formulation. The use of the standard solution has been found to be associated with hypermagnesemia and hypercalcemia, particularly if the patients are on high doses of calcium containing phosphate binders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Modified solutions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly used modifications to peritoneal dialysis solutions are low magnesium (0.5",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    and low calcium (2.5",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    dialysate (",
"    <a class=\"graphic graphic_table graphicRef51006 \" href=\"UTD.htm?37/2/37932\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18632/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Another modification that is available commercially contains low magnesium (0.5",
"    <span class=\"nowrap\">",
"     meq/L),",
"    </span>",
"    high calcium (3.5",
"    <span class=\"nowrap\">",
"     meq/L),",
"    </span>",
"    and high lactate concentration.",
"   </p>",
"   <p>",
"    These various formulations allow clinicians to tailor and individualize the peritoneal dialysis prescription based upon an individual's electrolyte and metabolic profile.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other additives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other additives are often added to the PD fluid in certain clinical situations. Some of the commonly used additives include insulin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , and antibiotics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insulin is frequently added to PD solutions in diabetics to help control hyperglycemia and offset the glucose load from the dextrose containing solutions. Intraperitoneal insulin has been found to be as good as subcutaneous insulin in the management of diabetes in PD patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7865?source=see_link\">",
"       \"Management of hyperglycemia in diabetics with end-stage renal disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      is frequently added to prevent the formation of fibrin in the PD fluid. This is particularly important during peritonitis episodes, when there is increased fibrin production as well as deposition of debris, which could lead to obstruction of the PD catheter. Intraperitoneal heparin does not lead to systemic anticoagulation in these patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7528?source=see_link\">",
"       \"Noninfectious complications of peritoneal dialysis catheters\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antibiotics are added to the peritoneal fluid to treat peritonitis. They are usually well tolerated and their absorption through the peritoneal membrane is enhanced during episodes of peritonitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=see_link\">",
"       \"Microbiology and therapy of peritonitis in continuous peritoneal dialysis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22270358\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peritoneal dialysis solutions primarily consist of water, osmotic agents, electrolytes and minerals. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Ideal solution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Osmotic agents allow net water removal by altering the osmotic pressure gradient between the peritoneal dialysis solution and plasma water. Dextrose is the most commonly used osmotic agent. Available dextrose concentrations include 1.5, 2.5, and 4.25 percent solutions. Amino acids may be used as an alternative to dextrose to improve nutritional status in peritoneal dialysis patients. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Low molecular weight agents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Dextrose concentrations'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      Buffers used to control acidosis include acetate, lactate, and bicarbonate. Lactate buffers are most commonly used and are commercially available in concentrations of 35 and 40",
"      <span class=\"nowrap\">",
"       mmol/L.",
"      </span>",
"      Acetate-based buffers cause pain during inflow and have been associated with sclerosing peritonitis. Bicarbonate-based buffers are not compatible with calcium and magnesium containing solutions, but can be mixed together immediately before use without problems. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Buffers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The sodium concentration in peritoneal dialysis solutions varies from 130 to 137",
"      <span class=\"nowrap\">",
"       mmol/L.",
"      </span>",
"      Nomograms are available to predict net sodium removal. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Sodium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal peritoneal dialysis calcium concentration is unclear. Many centers use low calcium concentrations (ie, 1.25",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      which can help in the treatment of hyperphosphatemia with calcium-containing phosphate binders. Hypocalcemia may develop in some patients who use low calcium dialysate, particularly those that are noncompliant with calcium-containing phosphate binders. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Calcium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The magnesium concentrations ranges from 0.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      to 1.5",
"      <span class=\"nowrap\">",
"       meq/L;",
"      </span>",
"      the 0.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      concentration is more commonly used since higher concentrations may cause hypermagnesemia. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Magnesium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potassium is usually not present in the commercial dialysate. Zero potassium dialysate tends to maintain serum potassium around 4",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      although some patients may develop hypokalemia. Hypokalemia",
"      <strong>",
"       could",
"      </strong>",
"      be corrected by the addition of 1 to 4",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      of potassium to the dialysate, but the strongly preferred method is to supplement potassium orally. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Potassium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peritoneal dialysis solutions are commonly available in 1 liter, 2 liter, 2.5 liter, 3 liter, 5 liter, and 6 liter bags. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Available dextrose based solutions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Volume'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"       Icodextrin",
"      </a>",
"      -containing solutions can cause falsely elevated glucose levels. In patients using icodextrin, blood glucose monitoring must be done with glucose-specific methods to prevent falsely elevated levels and subsequent inappropriate treatment of presumed hyperglycemia. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'High molecular weight agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Feriani, M, La Greca, et al. CAPD Systems and Solutions. In: Textbook of Peritoneal Dialysis, Gokal, R, Nolph, KD (Eds), Kluwer Academic Publishers, Netherlands 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/2\">",
"      Raja RM, Kramer MS, Manchanda R, et al. Peritoneal dialysis with fructose dialysate. Prevention of hyperglycemia and hyperosmolality. Ann Intern Med 1973; 79:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/3\">",
"      Bischel MD, Barbour BH. Peritoneal dialysis with sorbitol versus dextrose dialysate. Clinical findings and alterations of blood and cerebrospinal fluid. Nephron 1974; 12:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/4\">",
"      Matthys, E, Dolkart, R, Lameire, N. Extended use of glycerol containing dialysate in diabetic CAPD patients. Perit Dial Bull 1987; 7:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/5\">",
"      McIntyre CW. Update on peritoneal dialysis solutions. Kidney Int 2007; 71:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/6\">",
"      Vanholder RC, Lameire NH. Osmotic agents in peritoneal dialysis. Kidney Int Suppl 1996; 56:S86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/7\">",
"      Teitelbaum I, Burkart J. Peritoneal dialysis. Am J Kidney Dis 2003; 42:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/8\">",
"      Gokal R. Peritoneal dialysis solutions: nutritional aspects. Perit Dial Int 1997; 17 Suppl 3:S69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/9\">",
"      Stein, A, Peers, E, Hattersley, J, et al. Clinical experience with icodextrin in CAPD patients. Perit Dial Int 1994; 14 Suppl:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/10\">",
"      Lee JH, Reddy DK, Saran R, et al. Advanced glycosylation end-products in diabetic rats on peritoneal dialysis using various solutions. Perit Dial Int 2000; 20:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/11\">",
"      Plum J, Gentile S, Verger C, et al. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis. Am J Kidney Dis 2002; 39:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/12\">",
"      Finkelstein F, Healy H, Abu-Alfa A, et al. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol 2005; 16:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/13\">",
"      Diaz-Buxo JA, Passlick-Deetjen J, Gotloib L. Potential hazards of polyglucose. ASAIO J 2001; 47:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/14\">",
"      Seow, YY. Icodextrin-associated peritonitis among CAPD patients. Nephrol Dial Transplant 2003; 18:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/15\">",
"      Baxter Extraneal hypoglycemia testing program is condition of FDA approval. \"The Pink Sheet\" 2003; 65(1):6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/16\">",
"      Riley SG, Chess J, Donovan KL, Williams JD. Spurious hyperglycaemia and icodextrin in peritoneal dialysis fluid. BMJ 2003; 327:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/17\">",
"      Flor&eacute; KM, Delanghe JR. Analytical interferences in point-of-care testing glucometers by icodextrin and its metabolites: an overview. Perit Dial Int 2009; 29:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/18\">",
"      Han SH, Ahn SV, Yun JY, et al. Effects of icodextrin on patient survival and technique success in patients undergoing peritoneal dialysis. Nephrol Dial Transplant 2012; 27:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/19\">",
"      Klein E, Ward RA, Williams TE, Feldhoff PW. Peptides as substitute osmotic agents for glucose in peritoneal dialysate. ASAIO Trans 1986; 32:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/20\">",
"      Imholz AL, Lameire N, Faict D, et al. Evaluation of short-chain polypeptides as an osmotic agent in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1994; 14:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/21\">",
"      Hain H, Sch&uuml;tte W, Pustelnik A, et al. Ultrafiltration and absorption characteristics of hydroxyethylstarch and dextran during long dwell peritoneal dialysis exchanges in rats. Adv Perit Dial 1989; 5:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/22\">",
"      Grodstein GP, Blumenkrantz MJ, Kopple JD, et al. Glucose absorption during continuous ambulatory peritoneal dialysis. Kidney Int 1981; 19:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/23\">",
"      Sitter T, Sauter M. Impact of glucose in peritoneal dialysis: saint or sinner? Perit Dial Int 2005; 25:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/24\">",
"      Williams JD, Topley N, Craig KJ, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/25\">",
"      Lee HY, Park HC, Seo BJ, et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 2005; 25:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/26\">",
"      Johnson DW, Brown FG, Clarke M, et al. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol 2012; 23:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/27\">",
"      Lui SL, Yung S, Yim A, et al. A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial. Am J Kidney Dis 2012; 60:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/28\">",
"      Woodrow G. Can biocompatible dialysis fluids improve outcomes in peritoneal dialysis patients? Perit Dial Int 2005; 25:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/29\">",
"      Diaz-Buxo JA, Gotloib L. Agents that modulate peritoneal membrane structure and function. Perit Dial Int 2007; 27:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/30\">",
"      Ikizler TA, Hakim RM. Nutrition in end-stage renal disease. Kidney Int 1996; 50:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/31\">",
"      Young GA, Kopple JD, Lindholm B, et al. Nutritional assessment of continuous ambulatory peritoneal dialysis patients: an international study. Am J Kidney Dis 1991; 17:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/32\">",
"      Blumenkrantz MJ, Gahl GM, Kopple JD, et al. Protein losses during peritoneal dialysis. Kidney Int 1981; 19:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/33\">",
"      Young GA, Brownjohn AM, Parsons FM. Protein losses in patients receiving continuous ambulatory peritoneal dialysis. Nephron 1987; 45:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/34\">",
"      Bergstr&ouml;m J, F&uuml;rst P, Alvestrand A, Lindholm B. Protein and energy intake, nitrogen balance and nitrogen losses in patients treated with continuous ambulatory peritoneal dialysis. Kidney Int 1993; 44:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/35\">",
"      Jones MR, Gehr TW, Burkart JM, et al. Replacement of amino acid and protein losses with 1.1% amino acid peritoneal dialysis solution. Perit Dial Int 1998; 18:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/36\">",
"      Shockley TR, Martis L, Tranaeus AP. New solutions for peritoneal dialysis in adult and pediatric patients. Perit Dial Int 1999; 19 Suppl 2:S429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/37\">",
"      Garosi G, Gaggiotti E, Monaci G, et al. Biocompatibility of a peritoneal dialysis solution with amino acids: histological evaluation in the rabbit. Perit Dial Int 1998; 18:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/38\">",
"      Kopple JD, Bernard D, Messana J, et al. Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int 1995; 47:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/39\">",
"      Faller, B. Amino acid based peritoneal dialysis solutions. Kidney Int Suppl 1996; 50:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/40\">",
"      Bazzato G, Coli U, Landini S, et al. Xylitol as osmotic agent in CAPD: an alternative to glucose for uremic diabetic patients? Trans Am Soc Artif Intern Organs 1982; 28:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/41\">",
"      Heaton A, Ward MK, Johnston DG, et al. Evaluation of glycerol as an osmotic agent for continuous ambulatory peritoneal dialysis in end-stage renal failure. Clin Sci (Lond) 1986; 70:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/42\">",
"      Feriani, M. Buffers: Bicarbonate, lactate, and pyruvate. Kidney Int Suppl 1996; 50:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/43\">",
"      Mactier RA, Sprosen TS, Gokal R, et al. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int 1998; 53:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/44\">",
"      Feriani M, Kirchgessner J, La Greca G, Passlick-Deetjen J. Randomized long-term evaluation of bicarbonate-buffered CAPD solution. Kidney Int 1998; 54:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/45\">",
"      Feriani M, Dissegna D, La Greca G, Passlick-Deetjen J. Short-term clinical study with bicarbonate-containing peritoneal dialysis solution. Perit Dial Int 1993; 13:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/46\">",
"      Cancarini GC, Faict D, De Vos C, et al. Clinical evaluation of a peritoneal dialysis solution with 33 mmol/L bicarbonate. Perit Dial Int 1998; 18:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/47\">",
"      Feriani M, Passlick-Deetjen J, Jaeckle-Meyer I, et al. Individualized bicarbonate concentrations in the peritoneal dialysis fluid to optimize acid-base status in CAPD patients. Nephrol Dial Transplant 2004; 19:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/48\">",
"      Montenegro J, Saracho RM, Mart&iacute;nez IM, et al. Long-term clinical experience with pure bicarbonate peritoneal dialysis solutions. Perit Dial Int 2006; 26:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/49\">",
"      Montenegro J, Saracho R, Gallardo I, et al. Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis. Nephrol Dial Transplant 2007; 22:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/50\">",
"      Ahmad S, Sehmi JS, Ahmad-Zakhi KH, et al. Impact of new dialysis solutions on peritonitis rates. Kidney Int Suppl 2006; :S63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/51\">",
"      Gupta A, Amin NB, Besarab A, et al. Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Kidney Int 1999; 55:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/52\">",
"      Bastani B, Galley S. Intraperitoneal iron-dextran as a potential route of iron therapy in CAPD patients. Perit Dial Int 1996; 16:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/53\">",
"      S&aacute;nchez C, L&oacute;pez-Barea F, S&aacute;nchez-Cabezudo J, et al. Low vs standard calcium dialysate in peritoneal dialysis: differences in treatment, biochemistry and bone histomorphometry. A randomized multicentre study. Nephrol Dial Transplant 2004; 19:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/54\">",
"      Bro S, Brandi L, Daugaard H, Olgaard K. Calcium concentration in the CAPD dialysate: what is optimal and is there a need to individualize? Perit Dial Int 1997; 17:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18632/abstract/55\">",
"      Weinreich, T. Low or high calcium dialysate solutions in peritoneal dialysis? Kidney Int Suppl 1999; 50:s92.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1905 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-FE77A46CF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_12_18632=[""].join("\n");
var outline_f18_12_18632=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22270358\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IDEAL SOLUTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CONSTITUENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Osmotic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - High molecular weight agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Low molecular weight agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Buffers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Lactate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Acetate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Bicarbonate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Electrolytes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Sodium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Calcium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Magnesium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Potassium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      AVAILABLE DEXTROSE BASED SOLUTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Dextrose concentrations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Formulations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Standard solution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Modified solutions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other additives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22270358\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1905\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1905|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/0/6155\" title=\"table 1\">",
"      Standard PD solution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/2/37932\" title=\"table 2\">",
"      Comparison PD solutions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=related_link\">",
"      Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7865?source=related_link\">",
"      Management of hyperglycemia in diabetics with end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/63/33784?source=related_link\">",
"      Mechanisms of solute clearance and ultrafiltration in peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=related_link\">",
"      Microbiology and therapy of peritonitis in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7528?source=related_link\">",
"      Noninfectious complications of peritoneal dialysis catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14519?source=related_link\">",
"      Nutritional status and protein intake in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9274?source=related_link\">",
"      Pathogenesis and treatment of malnutrition in maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=related_link\">",
"      Treatment of hyperphosphatemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=related_link\">",
"      Use of iron preparations in hemodialysis patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_12_18633="Nevirapine: Drug information";
var content_f18_12_18633=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nevirapine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/15/25845?source=see_link\">",
"    see \"Nevirapine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/46/9961?source=see_link\">",
"    see \"Nevirapine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Viramune&reg;;",
"     </li>",
"     <li>",
"      Viramune&reg; XR&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F200899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Auro-Nevirapine;",
"     </li>",
"     <li>",
"      Mylan-Nevirapine;",
"     </li>",
"     <li>",
"      Teva-Nevirapine;",
"     </li>",
"     <li>",
"      Viramune&reg;;",
"     </li>",
"     <li>",
"      Viramune&reg; XR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F200935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Reverse Transcriptase Inhibitor (Non-nucleoside)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F200903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     <b>",
"      HIV infection:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Therapy in antiretroviral naive patients should not be initiated in patients with elevated CD4",
"     <sup>",
"      +",
"     </sup>",
"     -cell counts unless the benefit of therapy outweighs the risk of serious hepatotoxicity (adult/postpubertal females: CD4",
"     <sup>",
"      +",
"     </sup>",
"     -cell counts &gt;250 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; adult males: CD4",
"     <sup>",
"      +",
"     </sup>",
"     -cell counts &gt;400 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Initial:",
"     <i>",
"      Immediate release:",
"     </i>",
"     200 mg once daily for 14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maintenance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Immediate release:",
"     </i>",
"     200 mg twice daily (in combination with additional antiretroviral agents) if there is no rash or untoward effects during initial dosing period",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Extended release:",
"     </i>",
"     400 mg once daily; maintenance therapy using the extended release must follow a 14-day initial dosing period (lead-in) using the immediate release formulation unless patient is already maintained on a nevirapine immediate release regimen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If patient experiences a rash during the 14-day lead-in period, dose should not be increased until the rash has resolved. A lead-in period must always be done with immediate release formulation and regimen should not exceed 28 days; alternative treatment should be considered at that point. If a rash occurs within the first 18 weeks of therapy, immediately check serum transaminases. Discontinue if severe rash, rash with constitutional symptoms, or rash with elevated hepatic transaminases is noted. Coadministration of prednisone during the first 6 weeks of therapy increases incidence and severity of rash; concomitant prednisone is not recommended to prevent rash. Permanently discontinue if symptomatic hepatic events occur. If therapy with any formulation is interrupted for &gt;7 days, restart with initial dose of immediate release formulation for 14 days.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F200921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/46/9961?source=see_link\">",
"      see \"Nevirapine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      HIV infection:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If patient experiences a rash during the 14-day lead-in period, dose should not be increased until the rash has resolved. A lead-in period must always be done with immediate release formulation and regimen should not exceed 28 days; alternative treatment should be considered at that point. If a rash occurs within the first 18 weeks of therapy, immediately check serum transaminases. Discontinue if severe rash, rash with constitutional symptoms, or rash with elevated hepatic transaminases is noted. Coadministration of prednisone during the first 6 weeks of therapy increases incidence and severity of rash; concomitant prednisone is not recommended to prevent rash. Permanently discontinue if symptomatic hepatic events occur. If therapy with any formulation is interrupted for &gt;7 days, restart with initial dose of immediate release formulation for 14 days. Use of nevirapine in children &lt;15 years of age is not approved in the Canadian labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children:",
"     <i>",
"      Immediate release:",
"     </i>",
"     150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for first 14 days (maximum: 200 mg daily); increase dose to 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily if no rash or untoward effects (maximum: 400 mg daily).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6 to &lt;18 years:",
"     <i>",
"      Extended release:",
"     </i>",
"     Dose based on body surface area (Mosteller formula); maintenance therapy using the extended release must follow a 14-day initial dosing period (lead-in) using the immediate release formulation unless patient is already maintained on a nevirapine immediate release regimen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     0.58 m",
"     <sup>",
"      2",
"     </sup>",
"     to 0.83 m",
"     <sup>",
"      2",
"     </sup>",
"     : 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     0.84 m",
"     <sup>",
"      2",
"     </sup>",
"     to 1.16 m",
"     <sup>",
"      2",
"     </sup>",
"     : 300 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;1.17 m",
"     <sup>",
"      2",
"     </sup>",
"     : 400 mg once daily (do not exceed 400 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DHHS pediatric guidelines:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Children &lt;3 years of age: Nevirapine-based initial regimens should not be used in children previously exposed to nevirapine during prevention of maternal-to-child transmission of HIV",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &lt;8 years:",
"     <i>",
"      Immediate release:",
"     </i>",
"     200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for first 14 days (maximum dose: 200 mg); increase dose to 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily if no rash or untoward effects (maximum: 400 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;8 years:",
"     <i>",
"      Immediate release:",
"     </i>",
"     120-150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 14 days (maximum dose: 200 mg); increase dose to 120-150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily if no rash or untoward effects (maximum: 400 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents:",
"     <i>",
"      Immediate release:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Prevention of maternal-fetal HIV transmission (DHHS [perinatal], 2012): Note:",
"     </b>",
"     Nevirapine is used in combination with zidovudine in select situations (eg, infants born to mothers with only intrapartum therapy or no therapy). Use is not recommended in women receiving standard recommended antenatal antiretroviral prophylaxis.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F200904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F200905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Immediate release:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;20 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Extended release:",
"     </i>",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: An additional 200 mg",
"     <i>",
"      immediate release",
"     </i>",
"     dose is recommended following dialysis.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F200906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Permanently discontinue if symptomatic hepatic events occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild impairment (Child-Pugh class A):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Immediate release:",
"     </i>",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Extended release:",
"     </i>",
"     Not studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate-to-severe impairment (Child-Pugh class B or C): Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild impairment (Child-Pugh class A): No dosage adjustment is necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate impairment (Child-Pugh class B): No dosage adjustment provided in manufacturer&rsquo;s labeling. Use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment (Child-Pugh class C): Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F200874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 50 mg/5 mL (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Viramune&reg;: 50 mg/5 mL (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Viramune&reg;: 200 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Viramune&reg; XR&trade;: 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F200858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release tablet",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F15838439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Viramune XR&reg; 100 mg tablet: FDA approved November 2012; expected availability of the 100 mg extended release tablet is currently undetermined. The Viramune XR&reg; 400 mg tablets remain available.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089818.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089818.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F200877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be administered with or without food; may be administered with an antacid or didanosine. Shake suspension gently prior to administration; the use of an oral dosing syringe is recommended, especially if the dose is &le;5 mL; if using a dosing cup, after administration, rinse cup with water and also administer rinse. Extended release tablets must be swallowed whole and not crushed, chewed, or divided.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F200875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In combination therapy with other antiretroviral agents for the treatment of HIV-1",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F200943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nevirapine may be confused with nelfinavir",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Viramune&reg;, Viramune&reg; XR&trade; may be confused with Viracept&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F200933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Potentially life-threatening nevirapine-associated adverse effects may present with the following symptoms: Abrupt onset of flu-like symptoms, abdominal pain, jaundice, or fever with or without rash; may progress to hepatic failure with encephalopathy. Skin rash is present in ~50% of cases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (1% to 7%; grade 1/2: 13%; grade 3/4: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Cholesterol increased (240-300 mg/dL: 18% to 19%; &gt;300 mg/dL: 3% to 4%), LDL increased (160-190 mg/dL: 15%; &gt;190 mg/dL: 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (4% to 13%; grades 3/4: 1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (2.6-5 x ULN: 10% to 13%; &ge;5.1 x ULN: 6% to 7%), symptomatic hepatic events (including hepatitis and hepatic failure: 2% to 11%; risk higher in ARV-naive women with CD4 counts &gt;250 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     and ARV-naive men with CD4 counts &gt;400 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (&le;5%), headache (1% to 4%), fever (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (&lt;1% to 9%), amylase increased (1.6-5 x ULN: 7% to 8%; &ge;5.1 x ULN: &lt;1%), abdominal pain (&le;2%), diarrhea (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: AST increased (&ge;5.1 x ULN: 4% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reactions, anaphylaxis, anemia, angioedema, bullous eruptions, cholestatic hepatitis, conjunctivitis, eosinophilia, fulminant hepatitis, granulocytopenia, hepatic necrosis, hypersensitivity syndrome, hypophosphatemia, immune reconstitution syndrome, jaundice, lymphadenopathy, oral lesions, redistribution/accumulation of body fat, renal dysfunction, rhabdomyolysis, Stevens-Johnson syndrome, toxic epidermal necrolysis, ulcerative stomatitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F200880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Moderate-to-severe hepatic impairment (Child-Pugh class B or C); use in occupational or nonoccupational postexposure prophylaxis (PEP) regimens",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Clinically significant hypersensitivity to nevirapine or any component of the formulation; therapy rechallenge in patients with prior hypersensitivity reactions, severe rash, rash accompanied by constitutional symptoms, or clinical hepatitis due to nevirapine; severe hepatic dysfunction or AST or ALT &gt;5 times ULN (pretreatment or during prior use of nevirapine); hereditary conditions of galactose intolerance (eg, galactosemia, Lapp lactase deficiency, glucose-galactose malabsorption); concomitant use of herbal products containing St John&rsquo;s wort",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F200862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Severe hepatotoxic reactions may occur (fulminant and cholestatic hepatitis, hepatic necrosis) and, in some cases, have resulted in hepatic failure and death.",
"     </b>",
"     The greatest risk of these reactions is within the initial 6 weeks of treatment;",
"     <b>",
"      intensive monitoring is required during the initial 18 weeks of therapy to detect potentially life-threatening hepatic reactions.",
"     </b>",
"     Patients with a history of chronic hepatitis (B or C) or increased baseline transaminase levels may be at increased risk of hepatotoxic reactions. Female gender and patients with increased CD4",
"     <sup>",
"      +",
"     </sup>",
"     -cell counts may be at substantially greater risk of hepatic events (often associated with rash). Therapy in antiretroviral naive patients should not be started with elevated CD4",
"     <sup>",
"      +",
"     </sup>",
"     -cell counts unless the benefit of therapy outweighs the risk of serious hepatotoxicity. If signs and symptoms of hepatitis occur, nevirapine should be permanently discontinued with immediate evaluation of liver function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rhabdomyolysis: Has been observed in conjunction with skin and/or hepatic adverse events during postmarketing surveillance. Termination of therapy is warranted with evidence of severe skin or liver toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Severe life-threatening skin reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, hypersensitivity reactions with rash and organ dysfunction), including fatal cases, have occurred. The greatest risk of these reactions is within the initial 6 weeks of treatment; intensive monitoring is required during the initial 18 weeks of therapy to detect potentially life-threatening dermatologic and hypersensitivity reactions.",
"     </b>",
"     If a rash occurs within the first 18 weeks of therapy, immediately check serum transaminases. Risk is greatest in African-Americans, Asian, or Hispanic race/ethnicity or in females (DHHS, 2011). If a severe dermatologic or hypersensitivity reaction occurs, nevirapine should be permanently discontinued; these events may include a severe rash, or a rash associated with fever, blisters, oral lesions, conjunctivitis, facial edema, muscle or joint aches, transaminase increases, general malaise, hepatitis, eosinophilia, granulocytopenia, lymphadenopathy, or renal dysfunction. Use of the 14-day lead-in dosing period is necessary to decrease the incidence of rash events. If nonsevere rash (in absence of transaminase elevations) occurs, do not increase dose until resolution of rash. Coadministration of prednisone during the first 6 weeks of therapy increases incidence and severity of rash; concomitant prednisone is not recommended to prevent rash.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with pre-existing dysfunction; monitor closely for drug-induced hepatotoxicity. U.S. labeling contraindicates use in patients with moderate-to-severe impairment (Child-Pugh class B or C). Canadian labeling contraindicates use in severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	 Efavirenz: Use with nevirapine may increase the risk for adverse effects without increasing efficacy; concurrent use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use with caution in patients taking strong CYP3A4 inhibitors, moderate or strong CYP3A4 inducers and major CYP3A4 substrates (see Drug Interactions); consider alternative agents that avoid or lessen the potential for CYP-mediated interactions. Concurrent use of St John's wort is not recommended (Canadian labeling contraindicates concurrent use) as it may decrease the therapeutic efficacy of nevirapine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Nevirapine-based initial regimens should not be used in children &lt;3 years of age if previously exposed to nevirapine during prevention of maternal-to-child transmission of HIV due to increased risk of resistance and treatment failure. Protease inhibitor-based initial regimens preferred in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: When initiating therapy, a 14-day lead-in dose with the immediate release formulation should be used to decrease risk of skin reactions. If rash appears during the 14-day lead-in period, do not increase the dose or initiate the extended release formulation until the rash has resolved. An alternative regimen should be used if the lead-in dose period exceeds 28 days. Therapy in antiretroviral naive patients should not be initiated in patients with elevated CD4",
"     <sup>",
"      +",
"     </sup>",
"     -cell counts unless the benefit of therapy outweighs the risk of serious hepatotoxicity (adult/postpubertal females: CD4",
"     <sup>",
"      +",
"     </sup>",
"     -cell counts &gt;250 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; adult males: CD4",
"     <sup>",
"      +",
"     </sup>",
"     -cell counts &gt;400 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ). If CD4",
"     <sup>",
"      +",
"     </sup>",
"     -cell counts increase above these thresholds as a result of nevirapine-containing therapy, therapy may be continued. After the lead-in period, patients may be switched to the extended-release formulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Resistance: Due to rapid emergence of resistance, nevirapine should not be used as monotherapy or the only agent added to a failing regimen for the treatment of HIV. Use care when timing discontinuation of regimens containing nevirapine; levels are sustained after levels of other medications decrease, leading to nevirapine resistance. Cross-resistance may be conferred to other non-nucleoside reverse transcriptase inhibitors (DHHS, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F200929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (minor), CYP2D6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2D6 (weak), CYP3A4 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP2B6 (strong), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F200867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Nevirapine. Nevirapine may decrease the serum concentration of Atazanavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Boceprevir.  Management: Avoid strong CYP3A4 inducers with boceprevir when possible, and closely monitor response to boceprevir if such a combination cannot be avoided. Carbamazepine, phenytoin, phenobarbital, rifampin, and St. John's wort are considered contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caspofungin: Inducers of Drug Clearance may decrease the serum concentration of Caspofungin.  Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Nevirapine may decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Nevirapine may decrease the serum concentration of Contraceptives (Progestins).  Management: Instruct patients receiving nevirapine to use an alternative or additional nonhormonal contraceptive. Nevirapine product labeling however suggests that depo-medroxyprogesterone acetate may be used as a sole method of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inducers (Strong) may increase the metabolism of CYP2B6 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May enhance the adverse/toxic effect of Nevirapine. Nevirapine may enhance the adverse/toxic effect of Efavirenz. Nevirapine may decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Etravirine. This has been observed with the NNRTIs efavirenz and nevirapine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Etravirine. This has been observed with delavirdine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Nevirapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: Nevirapine may decrease serum concentrations of the active metabolite(s) of Fosamprenavir.  Management: Coadministration of nevirapine and fosamprenavir is not recommended without concurrent ritonavir.  However, when nevirapine and fosamprenavir/ritonavir (twice daily) are used in combination, no dose adjustment is required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose (within the labeled dosage range) when such a combination is used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Nevirapine may decrease the serum concentration of Indinavir.  Management: Increased indinavir doses may be needed when used with nevirapine; however, specific dosing guidelines have not been established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Nevirapine may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Nevirapine may decrease the serum concentration of Ketoconazole (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: Nevirapine may decrease the serum concentration of Lopinavir.  Management: Avoid once daily use of lopinavir/ritonavir with nevirapine.  Avoid use of this combination in patients less than 6 months of age.  See lopinavir/ritonavir prescribing information for recommended dose increases in other patients.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the metabolism of Methadone.  Management: Methadone dosage adjustments will likely be required with efavirenz and nevirapine, and may be necessary with rilpivirine as well.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Nevirapine may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Nevirapine may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.  Management: Consider alternatives to nifedipine for patients who are using strong CYP3A4 inducers.  At least one specific brand of nifedipine (Adalat CC) lists this combination as contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PACLitaxel: Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the metabolism of PACLitaxel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: Nevirapine may decrease the serum concentration of Rifabutin. Nevirapine may increase the serum concentration of Rifabutin. Rifabutin may decrease the serum concentration of Nevirapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Nevirapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Rilpivirine. This mechanism applies to coadministration of delavirdine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Rilpivirine. This mechanism applies to coadministration of efavirenz, etravirine, and nevirapine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: Nevirapine may decrease the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Specifically, St. Johns Wort may increase the metabolism of Reverse Transcriptase Inhibitors (Non-Nucleoside).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Voriconazole. Management: Consider avoiding when possible. Use efavirenz with voriconazole only if voriconazole is dosed at 400 mg every 12 hours and efavirenz is dosed at 300 mg daily (adult doses) throughout therapy. Avoid Atripla (efavirenz/emtricitabine/tenofovir).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F200894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Nevirapine serum concentration may be decreased by St John's wort; avoid concurrent use.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F200869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F200884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. Nevirapine crosses the placenta. No increased risk of overall birth defects has been observed following first trimester exposure according to data collected by the antiretroviral pregnancy registry. Pharmacokinetics are not altered during pregnancy and dose adjustment is not needed. The DHHS Perinatal HIV Guidelines recommend nevirapine as the preferred NNRTI for use during pregnancy. Nevirapine may be initiated in pregnant women with a CD4",
"     <sup>",
"      +",
"     </sup>",
"     lymphocyte count &lt;250/mm",
"     <sup>",
"      3",
"     </sup>",
"     or continued in women who are virologically suppressed and tolerating therapy once pregnancy is detected (regardless of CD4",
"     <sup>",
"      +",
"     </sup>",
"     lymphocyte count); however,",
"     <b>",
"      do not",
"     </b>",
"     initiate therapy in pregnant women with a CD4",
"     <sup>",
"      +",
"     </sup>",
"     lymphocyte count &gt;250/mm",
"     <sup>",
"      3",
"     </sup>",
"     unless the benefit of therapy clearly outweighs the risk. Elevated transaminase concentrations at baseline may increase the risk of toxicity; the monitoring recommendation for transaminase levels is generally the same as in nonpregnant women. Hypersensitivity reactions (including hepatic toxicity and rash) are more common in women on NNRTI.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum antiretroviral (ARV) drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV), also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F200910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F200885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although breast-feeding is not recommended, nevirapine is excreted into breast milk and measurable in the serum of nursing infants. Maternal or infant antiretroviral therapy does not completely eliminate the risk of postnatal HIV transmission. In addition, multiclass resistant virus has been detected in breast-feeding infants despite maternal therapy. Therefore, in the United States, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, complete avoidance of breast-feeding by HIV-infected women is recommended to decrease potential transmission of HIV (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F200883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Nevirapine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/5 mL (240 mL): $155.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Viramune Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/5 mL (240 mL): $165.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Viramune XR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (30): $710.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Nevirapine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (60): $650.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Viramune Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (14): $178.86",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F200871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor CBC and viral load. Baseline liver function tests should be obtained prior to nevirapine&rsquo;s initiation. DHHS adult guidelines recommend serum transaminase monitoring every 2 weeks for the first 4 weeks of therapy, monthly for the first 18 weeks, then frequently thereafter. Patients receiving maintenance immediate release nevirapine who change to the extended release formulation should adhere to their regular monitoring schedule. DHHS adult guidelines recommend serum transaminase monitoring every 2 weeks for the first 4 weeks of therapy, then monthly for 3 months, followed by every 3-4 months. DHHS pediatric guidelines recommend serum transaminase monitoring every 2 weeks for the first 4 weeks of therapy, followed by every 4 months. Assess/evaluate AST/ALT immediately in any patients with a rash. Permanently discontinue if patient experiences severe rash, constitutional symptoms associated with rash, rash with elevated AST/ALT, or clinical hepatitis. Mild-to-moderate rash without AST/ALT elevation may continue treatment per discretion of prescriber. If mild-to-moderate urticarial rash, do not restart if treatment is interrupted.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F200886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ciplanevimune (CO);",
"     </li>",
"     <li>",
"      Hirapine (MY);",
"     </li>",
"     <li>",
"      Neravir (TH);",
"     </li>",
"     <li>",
"      Nevimune (IN);",
"     </li>",
"     <li>",
"      Nuo Lan Pin (CL);",
"     </li>",
"     <li>",
"      Viramune (AE, AR, AT, AU, BE, BF, BG, BH, BJ, BR, CH, CI, CL, CN, CO, CY, CZ, DE, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HN, HU, ID, IE, IL, IQ, IR, IT, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, OM, PE, PL, PT, PY, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SY, TN, TR, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F200861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a non-nucleoside reverse transcriptase inhibitor, nevirapine has activity against HIV-1 by binding to reverse transcriptase. It consequently blocks the RNA-dependent and DNA-dependent DNA polymerase activities including HIV-1 replication. It does not require intracellular phosphorylation for antiviral activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F200879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: &gt;90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely; V",
"     <sub>",
"      d",
"     </sub>",
"     : 1.2 L/kg; CSF penetration approximates 40% to 50% of plasma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: ~60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via CYP3A4 and CYP2B6 (hydroxylation to inactive compounds); may undergo enterohepatic recycling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 93% (immediate release tablet); ~75% (extended release tablet [relative to immediate release]); 91% (oral solution)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Decreases over 2- to 4-week time with chronic dosing due to autoinduction (ie, half-life = 45 hours initially and decreases to 25-30 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Immediate release: 4 hours; Extended release:~24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~81%, primarily as metabolites, &lt;3% as unchanged drug); feces (~10%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      D'Aquila RT, Hughes MD, Johnson VA, et al, &ldquo;Nevirapine, Zidovudine, and Didanosine Compared With Zidovudine and Didanosine in Patients With HIV-1 Infection. A Randomized, Double-Blind, Placebo-Controlled Trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1996, 124(12):1019-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/12/18633/abstract-text/8633815/pubmed\" id=\"8633815\" target=\"_blank\">",
"        8633815",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\" July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hammer SM, Kessler HA, and Saag MS, &ldquo;Issues in Combination Antiretroviral Therapy: A Review,&rdquo;",
"      <i>",
"       J Acquir Immune Defic Syndr",
"      </i>",
"      , 1994, 7(Suppl 2):24-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/12/18633/abstract-text/8263750/pubmed\" id=\"8263750\" target=\"_blank\">",
"        8263750",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Havlir DV and Lange JM, &ldquo;New Antiretrovirals and New Combinations,&rdquo;",
"      <i>",
"       AIDS",
"      </i>",
"      , 1998, 12(Suppl A):165-74.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hilts AE and Fish DN, &ldquo;Dosage Adjustment of Antiretroviral Agents in Patients With Organ Dysfunction,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1998, 55:2528-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/12/18633/abstract-text/9853641/pubmed\" id=\"9853641\" target=\"_blank\">",
"        9853641",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mueller BU, Sei S, Anderson B, et al, &ldquo;Comparison of Virus Burden in Blood and Sequential Lymph Node Biopsy Specimens From Children Infected With Human Immunodeficiency Virus,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1996, 129(3):410-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/12/18633/abstract-text/8804331/pubmed\" id=\"8804331\" target=\"_blank\">",
"        8804331",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weverling GJ, Lange JM, Jurriaans S, et al, &ldquo;Alternative Multidrug Regimen Provides Improved Suppression of HIV-1 Replication Over Triple Therapy,&rdquo;",
"      <i>",
"       AIDS",
"      </i>",
"      , 1998, 12(11):F117-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/12/18633/abstract-text/9708401/pubmed\" id=\"9708401\" target=\"_blank\">",
"        9708401",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, &ldquo;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,&rdquo; August 16, 2010. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9694 Version 53.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-6EBEB1F6CE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_12_18633=[""].join("\n");
var outline_f18_12_18633=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709170\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200898\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200899\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200935\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200903\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200921\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200904\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200905\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200906\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200874\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200858\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838439\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874746\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200877\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200875\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200943\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200933\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200880\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200862\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200929\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200867\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200894\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200869\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200884\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200910\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200885\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200883\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200871\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200886\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200861\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200879\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9694\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9694|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/15/25845?source=related_link\">",
"      Nevirapine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/46/9961?source=related_link\">",
"      Nevirapine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_12_18634="Initial treatment of limited stage diffuse large B cell lymphoma";
var content_f18_12_18634=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial treatment of limited stage diffuse large B cell lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/12/18634/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/12/18634/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/12/18634/contributors\">",
"     Jonathan W Friedberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/12/18634/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/12/18634/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/12/18634/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/12/18634/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/12/18634/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1428162\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 30 percent of patients with NHL [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. It is an aggressive NHL in which survival without treatment is measured in months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial treatment of DLBCL is dependent upon the extent of disease. For patients with NHL, disease stage is determined using the Ann Arbor staging system with Cotswold modification, originally developed for Hodgkin lymphoma. This staging system focuses on the number of tumor sites (nodal and extranodal), location, and the presence or absence of systemic (\"B\") symptoms (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 1",
"    </a>",
"    ). For treatment purposes, patients with DLBCL are generally classified as having either limited stage disease or advanced stage disease based upon whether or not the tumor can be contained within one irradiation field:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limited stage disease (usually Ann Arbor stage I or II) &mdash; Limited stage DLBCL can be contained within one irradiation field. This population accounts for 30 to 40 percent of patients with DLBCL. Limited stage DLBCL is treated primarily with combined modality therapy consisting of abbreviated systemic chemotherapy (three cycles), the recombinant anti-CD20 antibody",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , and involved field radiation therapy. Alternatively, full course (six to eight cycles) systemic chemotherapy plus rituximab without radiation therapy may be used.",
"     </li>",
"     <li>",
"      Advanced stage disease (usually Ann Arbor stage III or IV) &mdash; Advanced stage DLBCL cannot be contained within one irradiation field. This population accounts for 60 to 70 percent of patients with DLBCL. Advanced stage DLBCL is treated with systemic chemotherapy plus the recombinant anti-CD20 antibody",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link\">",
"       \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with bulky (&gt;10 cm) stage II disease and patients with stage IIB disease have a less favorable prognosis than those with non-bulky stage II disease without systemic B symptoms. Many clinicians treat such patients in a similar fashion to those with advanced stage disease. (See",
"    <a class=\"local\" href=\"#H1565172628\">",
"     'Bulky disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The initial treatment of limited stage DLBCL is discussed here; diagnosis, staging, prognostic measures, and the treatment of advanced stage DLBCL and relapsed disease are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33178?source=see_link\">",
"     \"Treatment of relapsed or refractory diffuse large B cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oncologic emergencies and treatment-related hematologic toxicities are common in the aggressive NHLs. Clinicians must always be alert to their potential presence, and be prepared to deal with them urgently and effectively. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Oncologic emergencies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1554321610\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;To best treat patients with NHL, the initial evaluation must establish the precise histologic subtype, the extent and sites of disease, and the performance status of the patient. General approaches to the diagnostic work-up and staging of non-Hodgkin lymphoma are presented separately (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 1",
"    </a>",
"    ). The pretreatment evaluation for patients with limited stage DLBCL is the same as that of patients with advanced stage DLBCL. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link&amp;anchor=H2#H2\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Pretreatment evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1554321906\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, for treatment purposes, limited stage DLBCL (usually Ann Arbor stage I or II) can be contained within one irradiation field. This population accounts for 30 to 40 percent of patients with DLBCL. Patients with bulky (&gt;10 cm) stage II disease have a prognosis similar to that of patients with stage III or IV disease and therefore need to be treated more aggressively (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1565172628\">",
"     'Bulky disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most patients with non-bulky limited stage DLBCL are treated with combined modality therapy consisting of abbreviated systemic chemotherapy (ie, three cycles of CHOP), the recombinant anti-CD20 antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , and involved field radiation therapy. Although prognosis varies according to the International Prognostic Index (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"     table 2",
"    </a>",
"    ), this treatment approach results in five- and 10-year overall survival rates of approximately 95 and 75 percent, respectively. An acceptable alternative is the administration of full course (six to eight cycles) systemic chemotherapy plus rituximab without radiation therapy. The administration of radiation therapy without chemotherapy is",
"    <strong>",
"     not",
"    </strong>",
"    recommended because it is associated with a relapse rate of approximately 70 percent and inferior survival when compared with chemotherapy plus radiation. (See",
"    <a class=\"local\" href=\"#H93465931\">",
"     'Radiation alone'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are some special scenarios (eg, testicular lymphoma) where additional therapy is required (eg, intrathecal chemotherapy). These are discussed in more detail below. (See",
"    <a class=\"local\" href=\"#H1565171719\">",
"     'Unusual sites of involvement'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93465924\">",
"    <span class=\"h2\">",
"     Chemotherapy with or without radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred treatment for most patients with non-bulky limited stage DLBCL is a combined modality approach, consisting of three cycles of R-CHOP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ) chemotherapy followed by locoregional radiation therapy (RT) (",
"    <a class=\"graphic graphic_table graphicRef63586 \" href=\"UTD.htm?22/2/22574\">",
"     table 3",
"    </a>",
"    ). An acceptable alternative is six to eight cycles of R-CHOP without RT. These two approaches appear to have similar long-term survival rates, but different toxicities. Combined modality therapy has less acute cardiac and hematologic toxicity. Short and long-term toxicities related to the radiation therapy are dependent upon the location of disease (and radiation fields). Treatment with full course chemotherapy without RT may be preferred in situations where RT is expected to have increased long-term toxicity. Examples include older adults with involvement of the oronasopharynx, younger women with mediastinal involvement, and patients with pelvic involvement.",
"   </p>",
"   <p>",
"    R-CHOP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef63586 \" href=\"UTD.htm?22/2/22574\">",
"     table 3",
"    </a>",
"    ) has become the preferred chemotherapy regimen for the treatment of DLBCL based upon numerous randomized trials that primarily included patients with advanced stage DLBCL. However, a small number of patients with limited stage disease were included in these studies and subset analyses suggest a benefit to adding rituximab therapy in this group. As an example, the randomized MabThera International (MInT) Trial, which demonstrated an overall survival benefit with the addition of rituximab to CHOP-like chemotherapy, included a large number of patients with stage II or bulky stage I disease (72 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients with bulky disease (defined differently by each country) and extranodal disease received radiation therapy. In this trial, patients with an International Prognostic Index (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"     table 2",
"    </a>",
"    ) of zero and no bulky disease treated with chemotherapy plus rituximab had significantly higher three-year event-free survival (89 versus 78 percent) and trend towards increased overall survival (98 versus 92 percent) when compared with those who received chemotherapy alone. These trials are described in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link&amp;anchor=H4#H4\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Rituximab containing regimens'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Choice of chemotherapy regimen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264593724\">",
"    <span class=\"h3\">",
"     Is radiation therapy necessary?",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, we prefer the use of abbreviated systemic chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    followed by involved field radiation therapy for most patients with limited stage DLBCL. However, treatment regimens that do not include radiation therapy are an acceptable alternative, especially for patients with relative contraindications to radiation therapy.",
"   </p>",
"   <p>",
"    There have been four multi-institutional randomized trials comparing chemotherapy plus radiation therapy versus chemotherapy alone for patients with limited stage aggressive lymphoma (including DLBCL). All of these trials were performed prior to the incorporation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    into the standard treatment of DLBCL. Each of these trials investigated different patient populations and treatment regimens. They have had mixed results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the SWOG 8736 trial, 401 patients with limited stage aggressive lymphoma (75 percent DLBCL) were randomly assigned to treatment with either eight cycles of CHOP chemotherapy or three cycles of CHOP plus involved field RT (40 to 55 Gy) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/7\">",
"       7",
"      </a>",
"      ]. At a median follow-up of 4.4 years, combination therapy with three cycles of CHOP plus involved field RT resulted in higher rates of five-year progression-free (77 versus 64 percent) and overall (82 versus 72 percent) survival. In addition, patients treated with combined modality therapy had lower rates of cardiac toxicity (zero versus 3.5 percent) and severe neutropenia (27 versus 35 percent).",
"      <br/>",
"      <br/>",
"      A post-hoc analysis of patients without any stage-adjusted IPI risk factors had a five-year survival rate of 94 percent after three cycles of CHOP plus RT [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/8\">",
"       8",
"      </a>",
"      ]. An update of this study, presented in abstract form, has indicated that with 10-year follow-up there were excess relapses in patients treated on the combined modality arm. This resulted in no difference in failure-free or overall survival between the two treatment arms and no evidence of a plateau in the survival curve. However, in those patients with one or more risk factors, the five-year overall survival was only 70 percent after the same treatment, suggesting that three cycles of CHOP was not sufficient chemotherapy for this subgroup of patients. This was further supported by a SWOG phase II study that used R-CHOP for three cycles and involved field irradiation with excellent results in the group with one or more risk factors [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The GELA LNH 93-1 trial compared three cycles of CHOP followed by involved-field RT to treatment with dose-intensified ACVBP (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31123?source=see_link\">",
"       vindesine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) followed by sequential consolidation without RT in 647 patients younger than 61 years with localized aggressive lymphoma (81 percent DLBCL) and no adverse prognostic factors according to the IPI (",
"      <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/10\">",
"       10",
"      </a>",
"      ]. ACVBP-based therapy resulted in significantly higher rates of event-free (82 versus 74 percent) and overall survival (90 versus 81 percent) at five years. ACVBP-based therapy was associated with more episodes of severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      infection. The use of different chemotherapy regimens in the two treatment arms precludes the ability to compare the role of RT in this setting.",
"     </li>",
"     <li>",
"      In the ECOG 1484 trial, 172 patients with stage I or stage II aggressive lymphoma (82 percent DLBCL) in complete remission after eight cycles of CHOP chemotherapy were randomly assigned to receive 30 Gy of involved-field RT or to observation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/11\">",
"       11",
"      </a>",
"      ]. RT resulted in a significantly higher rate of disease-free survival (69 versus 53 percent) and a trend towards improved overall survival (87 versus 73 percent) at five years.",
"     </li>",
"     <li>",
"      In the GELA LNH 93-4 trial, 576 patients older than 60 years with localized stage I or II aggressive lymphoma (80 percent DLBCL) and no adverse prognostic factors of the IPI (",
"      <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"       table 2",
"      </a>",
"      ) were randomly assigned to receive either four cycles of CHOP plus involved-field RT (40 Gy) or chemotherapy alone with four cycles of CHOP [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/12\">",
"       12",
"      </a>",
"      ]. When compared with CHOP alone, CHOP plus RT resulted in similar rates of event-free (64 versus 61 percent) and overall survival (68 versus 72 percent) at five years. Patients who received RT had a lower rate of relapse at the site of initial disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these trials suggest that combination therapy with abbreviated chemotherapy plus RT is at least as effective as a full course of the same chemotherapy regimen and is associated with a lower rate of relapse at the sites of initial disease. There are no randomized trials of abbreviated R-CHOP plus radiation therapy versus treatment with R-CHOP alone. Only uncontrolled prospective trials and retrospective analyses are available [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/9,13,14\">",
"     9,13,14",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An uncontrolled phase II trial reported excellent outcomes with four infusions of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      and three cycles of CHOP followed by 40 to 46 Gy of involved-field radiation in 60 patients with limited stage disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/9\">",
"       9",
"      </a>",
"      ]. At a median follow-up of 5.3 years, progression-free survival rates were 93 and 88 percent at two and four years, respectively. Overall survival rates were 95 and 92 percent at two and four years, respectively.",
"     </li>",
"     <li>",
"      The randomized MabThera International (MInT) Trial, which demonstrated an overall survival benefit with the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      to CHOP-like chemotherapy, included a 597 patients with stage II or bulky stage I disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/6\">",
"       6",
"      </a>",
"      ]. In this trial, patients with an International Prognostic Index (",
"      <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"       table 2",
"      </a>",
"      ) of zero and no bulky disease treated with six cycles of CHOP-like chemotherapy plus rituximab had three-year event-free and overall survival rates of 89 and 98 percent, respectively. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link&amp;anchor=H4#H4\">",
"       \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Rituximab containing regimens'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Initial data regarding 65 patients with limited stage DLBCL from a single institution suggest that the administration of a fourth cycle of R-CHOP to patients with a negative positron emission tomography (FDG-PET) scan after three cycles of R-CHOP results in a very low relapse rate (only one relapse in 49 patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/15\">",
"       15",
"      </a>",
"      ]. While intriguing, the follow-up is short and adjusting treatment based upon the results of FDG-PET scans remains experimental. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above studies demonstrate that combination therapy consisting of abbreviated chemotherapy (CHOP x 3) plus radiation therapy results in at least equivalent, if not improved, survival when compared with eight cycles of chemotherapy alone in patients with non-bulky limited stage disease over the first 10 years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/16\">",
"     16",
"    </a>",
"    ]. As combined modality therapy results in less toxicity than chemotherapy alone, we prefer this approach for our patients. Thus, for patients with limited DLBCL we suggest treatment with three cycles of R-CHOP (",
"    <a class=\"graphic graphic_table graphicRef63586 \" href=\"UTD.htm?22/2/22574\">",
"     table 3",
"    </a>",
"    ) followed by involved-field radiation rather than six to eight cycles of R-CHOP alone. In situations where radiation may have increased toxicity, we suggest an extended course of chemotherapy and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    without radiation therapy based largely on the MInT trial. Whether radiation therapy may be eliminated for patients who attain a negative FDG-PET scan after a short course of chemotherapy remains unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1554321920\">",
"    <span class=\"h3\">",
"     Radiation dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is controversy regarding the ideal dose of irradiation after abbreviated chemotherapy. Trials that have examined abbreviated chemotherapy followed by radiation therapy have used doses of radiation that have ranged from 30 to 50 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/7,9,11,17-19\">",
"     7,9,11,17-19",
"    </a>",
"    ]. While the majority of patients in the randomized trials examining chemotherapy alone versus abbreviated chemotherapy plus radiation received between 45 and 50 Gy of localized radiation therapy, subsequent studies have suggested that lower doses of radiation, in the range of 30 to 40 Gy, may be sufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/7,20-23\">",
"     7,20-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of radiation dose was examined in a phase III trial that included 640 sites of aggressive non-Hodgkin lymphoma (82 percent DLBCL, all stages of disease were included) that randomly assigned radiation at lower doses (30 Gy in 15 fractions) or higher doses (40 to 45 Gy in 20 to 23 fractions) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/23\">",
"     23",
"    </a>",
"    ]. At a median follow-up of 5.6 years, lower dose radiation resulted in similar rates of in-field progression (hazard ratio 0.98, 95% CI 0.68-1.4), progression-free survival (hazard ratio 1.09, 95% CI 0.73-1.61), and overall survival (hazard ratio 1.15, 95% CI 0.88-1.51). This is consistent with our clinical experience that suggests that for patients with non-bulky disease who have a complete response on PET scanning, radiation doses of 30 to 36 Gy produce excellent results. In this setting, an infield recurrence is rarely seen. In comparison, for patients with initial bulky disease or persistent PET positive disease after chemotherapy, higher doses of radiation (eg, 45 to 50 Gy) may be needed.",
"   </p>",
"   <p>",
"    Some well known side effects of irradiating specific organs are discussed in more detail separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mediastinal irradiation significantly increases the risks of coronary heart disease, heart failure, and valvular disorders. Use of anthracyclines further increased the risks of heart failure and valvular disorders associated with mediastinal irradiation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=see_link\">",
"       \"Cardiotoxicity of radiation therapy for malignancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Irradiation to structures of the head and neck can result in xerostomia, osteonecrosis of the jaw, loss of teeth, and hypothyroidism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link\">",
"       \"Management and prevention of complications of head and neck cancer during initial treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Breast irradiation can significantly increase the long term risk of developing breast cancer, especially among women who are radiated before the age of 30. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=see_link&amp;anchor=H25#H25\">",
"       \"Second malignancies after treatment of classical Hodgkin lymphoma\", section on 'Breast cancer'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1554321927\">",
"    <span class=\"h3\">",
"     Radiation field size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over time there has been a movement to decrease the field of radiation in order to limit acute and long-term toxicities while maintaining survival rates. Various definitions have been applied. For our discussion, the following definitions will be used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extended-field radiation &mdash; Radiation field includes not only the clinically involved nodes, but also the adjacent, clinically uninvolved sites (eg, mantle field or inverted-Y field).",
"     </li>",
"     <li>",
"      Involved-field radiation &mdash; Radiation field encompasses all of the clinically involved regions (eg, mediastinal plus low bilateral supraclavicular field, which covers the entire mediastinum for initial mediastinal involvement; ipsilateral axilla and lateral supraclavicular radiation for initial axillary involvement).",
"     </li>",
"     <li>",
"      Involved-node radiation &mdash; Radiation field includes pre- and post-chemotherapy nodal volumes plus a margin of healthy tissue &le;5 cm [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/24,25\">",
"       24,25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients receiving combined modality treatment, we use involved field irradiation. Involved-field radiation has less toxicity when compared with extended-field radiation and it is the radiation field used in most of the trials combining chemotherapy plus radiation described in the sections above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93465931\">",
"    <span class=\"h2\">",
"     Radiation alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of radiation therapy without chemotherapy is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for patients with limited stage DLBCL. When radiation is administered without chemotherapy in this setting, relapse outside of the radiation field is common, and this approach has inferior survival rates when compared with chemotherapy plus radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/17,18,26-31\">",
"     17,18,26-31",
"    </a>",
"    ]. However, in patients who are otherwise unable to tolerate any systemic chemotherapy, involved-field radiation may be used for palliation or for cure if the disease is limited. Patients unable to tolerate systemic chemotherapy may also have difficulty tolerating radiation therapy. Involved-field radiation alone results in five-year disease-free survival rates of less than 40 percent in patients with limited stage aggressive lymphoma, such as DLBCL [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1554321934\">",
"    <span class=\"h2\">",
"     Our general approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients with non-bulky limited stage DLBCL, we suggest treatment with abbreviated chemotherapy (R-CHOP x 3) plus involved-field radiotherapy (45 Gy) rather than extended chemotherapy (R-CHOP x 6 to 8) alone (",
"    <a class=\"graphic graphic_table graphicRef63586 \" href=\"UTD.htm?22/2/22574\">",
"     table 3",
"    </a>",
"    ). In cases where radiation may cause significant morbidity (eg, involvement of the oronasopharynx or pelvis), the dose of chemotherapy is maximized to allow delivery of a more tolerable radiation dose [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/32\">",
"     32",
"    </a>",
"    ]. For example, chemotherapy alone may be indicated in young women in whom the breast would otherwise have to be irradiated and in those in whom radiation to the salivary glands might lead to loss of their teeth [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/33\">",
"     33",
"    </a>",
"    ]. Patients with bulky stage (&gt;10 cm) stage I or II disease may require more aggressive therapy. (See",
"    <a class=\"local\" href=\"#H1565172628\">",
"     'Bulky disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As such, both the medical oncologist and radiation oncologist should be involved in the initial treatment planning for patients with limited stage DLBCL. This approach is estimated to result in two-year overall survival rates of approximately 95 percent.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    therapy carries a risk of hepatitis B reactivation among patients positive for HBsAg or anti-HBc. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1565171255\">",
"    <span class=\"h1\">",
"     SPECIAL SCENARIOS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general treatment principles for limited and advanced stage DLBCL apply to most disease presentations and patient populations. However, involvement of certain organs, particularly when occurring as primary sites of disease, has unique therapeutic implications. In addition, older adults and patients with cardiac disease or HIV infection require special consideration. In particular, patients with HIV infection or hepatitis infection should be managed in close collaboration with infectious disease experts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link&amp;anchor=H17#H17\">",
"     \"Management of gastrointestinal lymphomas\", section on 'Diffuse large B cell lymphoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link&amp;anchor=H15#H15\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'AIDS-related lymphoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link&amp;anchor=H326785256#H326785256\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Older adults'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link&amp;anchor=H14#H14\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Patients with cardiac disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1565172628\">",
"    <span class=\"h2\">",
"     Bulky disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with bulky (&gt;10 cm) stage II disease have a less favorable prognosis than those with non-bulky stage II disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/5\">",
"     5",
"    </a>",
"    ]. After eight cycles of R-CHOP alone, for example, five-year median survival for those with bulky disease is approximately 60 percent compared with 95 percent for patients with no bulky disease. This survival rate is similar to that observed among patients with stage III or IV DLBCL. Among patients with bulky (&gt;10 cm) stage I or II DLBCL we suggest the addition of involved-field radiation (30 to 40 Gy) after completion of six cycles of R-CHOP rather than six to eight cycles of R-CHOP alone or three cycles of R-CHOP followed by radiation therapy. Despite this more aggressive approach, survival rates of patients with bulky disease remain worse than for those of patients without bulky disease suggesting a need for trials targeting this population.",
"   </p>",
"   <p>",
"    The randomized MabThera International (MInT) Trial, which demonstrated an overall survival benefit with the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to six cycles of CHOP-like chemotherapy, included a small number of patients with masses &gt;10 cm (3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/6\">",
"     6",
"    </a>",
"    ]. All patients with bulky disease received adjuvant radiation. Three-year event-free survival rates of patients with early stage disease treated with R-CHOP were higher in those with tumors &lt;5 cm when compared with those with tumors &gt;10 cm (83 versus 73 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/34\">",
"     34",
"    </a>",
"    ]. Three-year overall survival rates were also higher for those with tumors &lt;5 cm when compared with those with tumors &gt;10 cm (98 versus 85 percent, respectively). Unfortunately, despite the addition of radiation, the presence of bulky disease remained a poor prognostic factor. These trials are described in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link&amp;anchor=H4#H4\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Rituximab containing regimens'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Choice of chemotherapy regimen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with bulky (&gt;10 cm) stage I or II DLBCL, we suggest the addition of involved-field radiation (30 to 40 Gy) after completion of six cycles of R-CHOP rather than eight cycles of R-CHOP alone. We prefer this approach because studies in non-bulky disease suggest that combined chemotherapy plus radiation therapy may be superior to chemotherapy alone, as well as less toxic. We choose six cycles of R-CHOP rather than eight because radiation therapy does not appear to add benefit to eight cycles and because maximum response to bulky disease is usually observed by six cycles of chemotherapy; this approach limits anthracycline exposure, which is particularly relevant if the heart is in the radiation field. In addition, six cycles were used in the MInT trial, which was the only trial of R-CHOP to include patients with bulky disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1565171719\">",
"    <span class=\"h2\">",
"     Unusual sites of involvement",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17320527\">",
"    <span class=\"h3\">",
"     Mediastinum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary mediastinal large B cell lymphoma (PMLBCL) is a distinct clinicopathologic entity accounting for approximately 7 percent of DLBCL cases. It often presents with a locally invasive anterior mediastinal mass with frequent airway compromise and superior vena cava syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9238?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of primary mediastinal large B-cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognosis and optimal treatment of PMLBCL are uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/35-40\">",
"     35-40",
"    </a>",
"    ]. For most patients with limited stage disease PMLBCL we advocate six cycles of R-CHOP followed by involved-field radiation. Patients with bulky disease, pericardial effusion, or pleural effusions are treated as advanced disease with eight cycles of R-CHOP (",
"    <a class=\"graphic graphic_table graphicRef63586 \" href=\"UTD.htm?22/2/22574\">",
"     table 3",
"    </a>",
"    ). For patients who have contraindications or relative contraindications to radiation therapy, a chemotherapy-only regimen may be considered. Examples include the combination of dose-dense R-CHOP followed by R-ICE consolidation or the combination of DA-EPOCH plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    There have been no prospective, randomized trials investigating choice of chemotherapy in patients with PMLBCL. In addition, most of the reported retrospective studies have not included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    therapy, which has become a standard component of DLBCL treatment. When compared with other forms of DLBCL, PMLBCL appears to have a higher rate of primary refractoriness and early relapse following CHOP-based therapy without rituximab and poor response rates with second line therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/41-47\">",
"     41-47",
"    </a>",
"    ]. However, initial reports have suggested that the addition of rituximab to the initial therapy of PMLBCL may overcome at least some of poor prognostic features of PMLBCL.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The randomized MabThera International (MInT) Trial of CHOP-like chemotherapy with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in patients younger than 60 years with DLBCL included patients with PMLBCL [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/6,48\">",
"       6,48",
"      </a>",
"      ]. A subset analysis of the 87 patients with PMLBCL reported that rituximab treatment resulted in a significant increase in the rate of complete remission (90 versus 54 percent), decrease in the rate of primary progressive disease (3 versus 24 percent), and increase in three-year event-free survival (78 versus 52 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/49\">",
"       49",
"      </a>",
"      ]. There was a trend towards increased overall survival at three years (89 versus 78 percent) that did not reach statistical significance but was similar in magnitude to the statistically significant survival benefit for patients with DLBCL overall. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link&amp;anchor=H4#H4\">",
"       \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Rituximab containing regimens'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reported in abstract form, a single institution case series of sequential dose-dense R-CHOP followed by ICE (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ) consolidation without radiotherapy in 54 patients with PMLBCL reported progression-free and overall survival rates of 78 and 88 percent, respectively, at three years [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/50\">",
"       50",
"      </a>",
"      ]. Of the 11 patients who progressed, five were successfully treated with a regimen that included radiation therapy to the mediastinum, high dose chemotherapy, and hematopoietic rescue with autologous stem cells.",
"     </li>",
"     <li>",
"      An abstract presentation reported initial results from a prospective case series of 58 patients treated with dose-adjusted",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (DA-EPOCH) alone (18 patients) or DA-EPOCH plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (40 patients) followed for a median of 10.9 and 3.3 years, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/51\">",
"       51",
"      </a>",
"      ]. Patients treated with rituximab had significantly higher rates of progression-free (93 versus 67 percent) and overall (100 versus 78 percent) survival. Two patients required additional treatment modalities (one surgery, one involved-field radiation) for the management of biopsy-proven residual disease after chemotherapy. Two patients relapsed with local disease and received combined modality therapy and radiation therapy alone, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given concerns over a possible worse prognosis, retrospective studies have evaluated the use of more intensive chemotherapy regimens such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    (MACOP-B) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/52\">",
"     52",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin (VACOP-B) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/52\">",
"     52",
"    </a>",
"    ], and the NHL-15 protocol (doxorubicin plus vincristine for induction followed by consolidation with cyclophosphamide) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/43\">",
"     43",
"    </a>",
"    ]. Although these retrospective studies suggest better outcomes with more intensive chemotherapy, these therapies also have greater potential side effects and risks associated with their administration and have not been evaluated in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    era. Prospective randomized trials of more intensive chemotherapy in other patients with DLBCL have not demonstrated improved survival. As such, without prospective randomized trials comparing the different regimens in this disease subset we use R-CHOP chemotherapy for these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Choice of chemotherapy regimen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the suggestion of improved outcome with the incorporation of radiation therapy, for most patients with limited stage disease PMLBCL we advocate six cycles of R-CHOP followed by involved-field radiation. Patients with bulky disease, pericardial effusion or pleural effusions are treated as advanced disease with eight cycles of R-CHOP (",
"    <a class=\"graphic graphic_table graphicRef63586 \" href=\"UTD.htm?22/2/22574\">",
"     table 3",
"    </a>",
"    ). For patients who have contraindications or relative contraindications to radiation therapy, a chemotherapy-only regimen may be considered. Examples include the combination of dose-dense R-CHOP followed by R-ICE consolidation or the combination of DA-EPOCH plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1565171727\">",
"    <span class=\"h3\">",
"     CNS involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system (CNS) involvement by DLBCL is not common at presentation and will occur at some point during the disease course in less than 10 percent of patients. Certain patient populations have higher rates of CNS involvement both at the time of diagnosis and at relapse. There is general agreement that patients with testicular, epidural, or paranasal sinus involvement are at high risk of developing CNS disease. The evidence for an increased risk of CNS relapse is less strong for other scenarios that we still consider high risk, such as patients with breast or ovarian involvement, concordant bone marrow involvement, a high International Prognostic Index (IPI), or multiple extranodal sites of disease. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link&amp;anchor=H23#H23\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients at increased risk of CNS involvement should undergo a lumbar puncture as part of their initial evaluation and chemotherapy-based CNS prophylaxis should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link&amp;anchor=H2#H2\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Pretreatment evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link&amp;anchor=H23#H23\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While there are data to suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    penetrates the CNS, CHOP, the initial chemotherapy regimen of choice for DLBCL, does not penetrate the CNS. As such, for patients with secondary involvement of the brain or spinal cord at the time of diagnosis, we administer specific treatment targeting these areas. Such treatment varies based upon the exact disease site, but can include intrathecal chemotherapy, systemic high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation to the sites of involvement. The treatment of CNS involvement is presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with neurologic compromise from spinal cord compression require urgent therapy that may include neurosurgical intervention. The timing of chemotherapy and radiation therapy is controversial; however, many patients are treated with radiation therapy prior to receiving systemic therapy. The benefit of intrathecal therapy, particularly in the presence of a normal spinal fluid evaluation, is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26970?source=see_link\">",
"     \"Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1565171734\">",
"    <span class=\"h3\">",
"     Testicular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular lymphoma is the most common malignant testicular tumor in men over 60 years and accounts for approximately 1 percent of lymphomas overall [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/53\">",
"     53",
"    </a>",
"    ]. DLBCL is the most common subtype and the median age of presentation is in the sixth to seventh decade [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/54\">",
"     54",
"    </a>",
"    ]. Outcomes in patients with testicular involvement are worse than would be predicted by the International Prognostic Index [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. In addition to systemic chemotherapy, the treatment of primary testicular lymphoma should incorporate irradiation of the involved-field and contralateral testis plus central nervous system (CNS) prophylaxis with either intrathecal chemotherapy or high dose systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Unilateral orchiectomy on the side of disease is usually performed initially to obtain diagnostic tissue. It is clear, however, that orchiectomy alone is not sufficient treatment even in the case of localized disease. A retrospective study of 29 patients with early stage testicular lymphoma found that patients treated with orchiectomy, radiation, and systemic chemotherapy had significantly higher four-year overall survival rates when compared with historic controls who had received orchiectomy plus radiation therapy alone (93 versus 50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even with systemic chemotherapy, relapse is often systemic and frequently involves the CNS or contralateral testis. As an example, one study of 29 patients with DLBCL with primary testicular involvement demonstrated that 41 percent of relapses were either in the CNS or the contralateral testis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/58\">",
"     58",
"    </a>",
"    ]. In another study of 373 patients with primary testicular lymphoma, 56 (15 percent) had CNS relapse",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progression [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/55\">",
"     55",
"    </a>",
"    ]. Approximately 65 percent of these relapses involved the brain parenchyma.",
"   </p>",
"   <p>",
"    Given the high rates of relapse at sites protected from the effects of systemic chemotherapy, prophylactic therapy directed at the testes and CNS should be given. There have been no prospective randomized trials that have evaluated the efficacy of testicular irradiation or intrathecal chemotherapy in testicular lymphoma. Data regarding the treatment of primary testicular lymphoma come from small retrospective studies and nonrandomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/53,55,59-65\">",
"     53,55,59-65",
"    </a>",
"    ]. These studies suggest higher survival rates in patients who receive radiation to the contralateral testis and CNS prophylaxis with either intrathecal chemotherapy or high dose systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest international prospective trial included 53 patients with untreated stage I or II primary testicular lymphoma and evaluated treatment with six to eight cycles of R-CHOP-21, four weekly doses of intrathecal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (12 mg), and radiation therapy to the contralateral testis (30 Gy) for all patients and to regional lymph nodes (30 to 36 Gy) for patients with stage II disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/65\">",
"       65",
"      </a>",
"      ]. With a median follow-up of 65 months, the following results were reported:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Three patients did not complete the planned",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      due to intolerance and toxicity. Six patients did not undergo the planned testicular radiation; one had a bilateral orchiectomy, one had disease progression, and four refused radiation.",
"     </li>",
"     <li>",
"      Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities included neutropenia (28 percent), infections (4 percent), and neurologic symptoms (13 percent).",
"     </li>",
"     <li>",
"      The rates of overall and progression-free survival at five years were 85 and 74 percent, respectively. Relapses occurred in the CNS (three patients), lymph nodes (two patients), and non-CNS extranodal organs (five patients). There were no relapses in the contralateral testis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the largest retrospective studies examined the use of systemic chemotherapy with (15 patients) or without (27 patients) involved field radiation therapy in patients with localized testicular lymphoma after orchiectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients who received both chemotherapy and involved-field radiation therapy had significantly superior three-year overall survival (approximately 80 versus 20 percent).",
"     </li>",
"     <li>",
"      Contralateral scrotal irradiation was given to 10 patients, none of whom had recurrence in the contralateral testis. By comparison, the contralateral testis was the initial site of relapse in 2 of 35 patients who did not receive contralateral scrotal irradiation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective review of 35 patients with testicular lymphoma reported CNS relapse in four of six patients who received systemic chemotherapy without intrathecal chemotherapy compared with CNS relapse in one of 12 patients who received both systemic chemotherapy (CHOP) and intrathecal chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective, nonrandomized trial of 34 patients with early stage testicular lymphoma evaluated response to a treatment regimen that consisted of orchiectomy, six cycles of anthracycline-based combined chemotherapy, radiation to the contralateral testis, and CNS prophylaxis with high dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/60\">",
"       60",
"      </a>",
"      ]. While a complete response was obtained in 97 percent, 21 patients relapsed at a median follow-up of 74 months. No relapses occurred in the CNS or in areas of irradiation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together these reports suggest a benefit to the combination of orchiectomy, systemic chemotherapy with CNS prophylaxis, followed by involved-field radiation therapy (eg, area of the involved scrotum) and contralateral scrotal irradiation. Given its low morbidity and suggested benefit, for patients with DLBCL with testicular involvement, we suggest the administration of both involved-field radiation and low dose radiation therapy to the contralateral testis. For patients with testicular lymphoma, we also recommend the administration of CNS prophylaxis in addition to systemic chemotherapy rather than chemotherapy alone. More details on CNS prophylaxis are given separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link&amp;anchor=H23#H23\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1565171759\">",
"    <span class=\"h3\">",
"     Ovarian",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary lymphoma of the ovary is an extremely uncommon neoplasm mostly reported in the literature as case reports or small case series. The most common presentation is of a painful abdominal or pelvic mass. Tumors are staged using the Federation International of Gynecologists and Obstetricians (FIGO) system used for other ovarian neoplasms (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"     table 4",
"    </a>",
"    ). Prognosis for DLBCL of the ovary is poor with two and five-year survival rates of approximately 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no clinical trials to guide the therapy of ovarian lymphoma. Initial treatment usually involves bilateral salpingo-oophorectomy with or without hysterectomy, although unilateral salpingo-oophorectomy may be acceptable if there is no evidence of disease on the contralateral side after careful inspection. Hysterectomy is not indicated, but is often performed if taking both ovaries to prevent problems with bleeding.",
"   </p>",
"   <p>",
"    Adjuvant R-CHOP chemotherapy is given according to stage. Involvement of this very rare site has been reported to be associated with recurrence in systemic sites, including the CNS, although the exact rate of CNS involvement is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?18/12/18634/abstract/66\">",
"     66",
"    </a>",
"    ]. For this reason, we suggest prophylaxis to the CNS for patients with lymphoma of the ovary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link&amp;anchor=H23#H23\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1565171766\">",
"    <span class=\"h3\">",
"     Breast",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary lymphoma of the breast usually presents as a painless breast mass. DLBCL is the most common subtype. There are limited data to guide treatment of such patients. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36150?source=see_link\">",
"     \"Breast lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1554322479\">",
"    <span class=\"h1\">",
"     PATIENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;After completion of the initially planned treatment of DLBCL, patients should be evaluated to determine the disease response to treatment and should be followed longitudinally for relapse. The follow-up of patients with limited stage DLBCL is the same as that of patients with advanced stage DLBCL. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link&amp;anchor=H26#H26\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Patient follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/19/26930?source=see_link\">",
"       \"Patient information: Diffuse large B-cell lymphoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/60/27588?source=see_link\">",
"       \"Patient information: Diffuse large B-cell lymphoma in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1554322733\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL). It is an aggressive NHL in which survival without treatment is measured in months. Limited stage disease (usually Ann Arbor stage I or II) is defined as that which can traditionally be contained within one irradiation field. This population accounts for less than 30 percent of patients with DLBCL. (See",
"      <a class=\"local\" href=\"#H1428162\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pretreatment evaluation both determines the extent of the disease and provides information about the individual's comorbidities that are likely to affect treatment options. In addition to a history and physical examination, it is our practice to perform laboratory studies, unilateral bone marrow biopsy, and imaging in all patients. Certain subsets of patients will require further testing of their cerebrospinal fluid and cardiac function. Fertility counseling should be offered to patients in childbearing years. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link&amp;anchor=H2#H2\">",
"       \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Pretreatment evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For most patients with non-bulky limited stage DLBCL, we suggest treatment with abbreviated chemotherapy plus involved-field radiotherapy rather than chemotherapy alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We administer three cycles of R-CHOP (",
"      <a class=\"graphic graphic_table graphicRef63586 \" href=\"UTD.htm?22/2/22574\">",
"       table 3",
"      </a>",
"      ) followed by 30 to 36 Gy of involved-field radiation. In cases where radiation may cause significant morbidity (eg, involvement of the oronasopharynx or pelvis), the dose of chemotherapy is maximized to allow delivery of a more tolerable radiation dose. Chemotherapy alone may be indicated, for example in young women in whom the breast would otherwise have to be irradiated, in those in whom radiation to the salivary glands might lead to loss of their teeth, or in patients who defer radiation therapy. (See",
"      <a class=\"local\" href=\"#H1554321906\">",
"       'Initial treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The general treatment principles for limited stage DLBCL apply to most disease presentations and patient populations. However, older adults and patients with cardiac disease or HIV infection require special consideration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link&amp;anchor=H1554322491#H1554322491\">",
"       \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Special scenarios'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with bulky (&gt;10 cm) stage I or II tumors, we suggest treatment with six cycles of R-CHOP followed by involved-field radiation rather than chemotherapy alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1565172628\">",
"       'Bulky disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with limited stage disease primary mediastinal large B cell lymphoma, we recommend treatment with chemotherapy plus involved-field radiotherapy rather than chemotherapy alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We administer six cycles of R-CHOP followed by involved-field radiation rather than the use of more intensive chemotherapy regimens. Patients with bulky primary mediastinal disease, pericardial effusion or pleural effusions are treated as advanced disease with eight cycles of R-CHOP. (See",
"      <a class=\"local\" href=\"#H17320527\">",
"       'Mediastinum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with DLBCL with testicular involvement, initial therapy consists of orchiectomy on the side of disease, low dose radiation therapy to the involved field and contralateral testis, systemic chemotherapy, and intrathecal chemotherapy. (See",
"      <a class=\"local\" href=\"#H1565171734\">",
"       'Testicular'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is general agreement that patients with testicular, epidural, or paranasal sinus involvement are at increased risk of developing CNS disease. The evidence for an increased risk of CNS relapse is less strong for other scenarios that we still consider high risk, such as patients with breast or ovarian involvement, concordant bone marrow involvement, a high International Prognostic Index (IPI), or multiple extranodal sites of disease. This is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link&amp;anchor=H23#H23\">",
"       \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\", section on 'Prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A combined positron emission",
"      <span class=\"nowrap\">",
"       tomography/computed",
"      </span>",
"      tomography scan",
"      <span class=\"nowrap\">",
"       (PET/CT)",
"      </span>",
"      should be obtained six to eight weeks after chemotherapy and 12 weeks after the completion of radiation therapy. Using information gathered from the post-treatment history, physical, and",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      scan, disease response is determined by the International Workshop Criteria (IWC) (",
"      <a class=\"graphic graphic_table graphicRef64921 \" href=\"UTD.htm?29/27/30140\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link&amp;anchor=H27#H27\">",
"       \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Response evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Following the completion of therapy, restaging, and documentation of complete remission, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. The frequency and extent of these visits depends upon the comfort of both the patient and physician. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link&amp;anchor=H28#H28\">",
"       \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Surveillance for relapse'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/1\">",
"      Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/2\">",
"      Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/3\">",
"      Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/5\">",
"      Miller TP. The limits of limited stage lymphoma. J Clin Oncol 2004; 22:2982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/6\">",
"      Pfreundschuh M, Tr&uuml;mper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/7\">",
"      Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998; 339:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/8\">",
"      Fisher RI, Miller TP, O'Connor OA. Diffuse aggressive lymphoma. Hematology Am Soc Hematol Educ Program 2004; :221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/9\">",
"      Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 2008; 26:2258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/10\">",
"      Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005; 352:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/11\">",
"      Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004; 22:3032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/12\">",
"      Bonnet C, Fillet G, Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007; 25:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/13\">",
"      Phan J, Mazloom A, Medeiros LJ, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 2010; 28:4170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/14\">",
"      Hong J, Kim AJ, Park JS, et al. Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis. Korean J Hematol 2010; 45:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/15\">",
"      Dunleavy K, Mikhaeel G, Sehn LH, et al. The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma. Leuk Lymphoma 2010; 51 Suppl 1:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/16\">",
"      Ballonoff A, Rusthoven KE, Schwer A, et al. Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: a surveillance, epidemiology, and end results analysis. Int J Radiat Oncol Biol Phys 2008; 72:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/17\">",
"      Chen MG, Prosnitz LR, Gonzalez-Serva A, Fischer DB. Results of radiotherapy in control of stage I and II non-Hodgkin's lymphoma. Cancer 1979; 43:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/18\">",
"      Jones SE, Miller TP, Connors JM. Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. J Clin Oncol 1989; 7:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/19\">",
"      Miller TP, LeBlanc M, Spier C, et al. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: update of the Soutwest Oncology Group (SWOG) randomized trial (abstract). Blood 2001; 98:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/20\">",
"      Wilder RB, Tucker SL, Ha CS, et al. Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy. Int J Radiat Oncol Biol Phys 2001; 49:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/21\">",
"      Connors JM, Klimo P, Fairey RN, Voss N. Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann Intern Med 1987; 107:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/22\">",
"      Yamashita H, Izutsu K, Nakamura N, et al. Treatment results of chemoradiation therapy for localized aggressive lymphomas: A retrospective 20-year study. Ann Hematol 2006; 85:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/23\">",
"      Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol 2011; 100:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/24\">",
"      Yu JI, Nam H, Ahn YC, et al. Involved-lesion radiation therapy after chemotherapy in limited-stage head-and-neck diffuse large B cell lymphoma. Int J Radiat Oncol Biol Phys 2010; 78:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/25\">",
"      Campbell BA, Connors JM, Gascoyne RD, et al. Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy. Cancer 2012; 118:4156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/26\">",
"      Kaminski MS, Coleman CN, Colby TV, et al. Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann Intern Med 1986; 104:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/27\">",
"      Sweet DL, Kinzie J, Gaeke ME, et al. Survival of patients with localized diffuse histiocytic lymphoma. Blood 1981; 58:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/28\">",
"      Spicer J, Smith P, Maclennan K, et al. Long-term follow-up of patients treated with radiotherapy alone for early-stage histologically aggressive non-Hodgkin's lymphoma. Br J Cancer 2004; 90:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/29\">",
"      Longo DL, Glatstein E, Duffey PL, et al. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. J Clin Oncol 1989; 7:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/30\">",
"      Tondini C, Zanini M, Lombardi F, et al. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas. J Clin Oncol 1993; 11:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/31\">",
"      Armitage JO, Cheson BD. Interpretation of clinical trials in diffuse large-cell lymphoma. J Clin Oncol 1988; 6:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/32\">",
"      Shikama N, Ikeda H, Nakamura S, et al. Localized aggressive non-Hodgkin's lymphoma of the nasal cavity: a survey by the Japan Lymphoma Radiation Therapy Group. Int J Radiat Oncol Biol Phys 2001; 51:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/33\">",
"      Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood 2007; 110:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/34\">",
"      Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 2008; 9:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/35\">",
"      Abou-Elella AA, Weisenburger DD, Vose JM, et al. Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 43 patients from the Nebraska Lymphoma Study Group. J Clin Oncol 1999; 17:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/36\">",
"      van Besien K, Kelta M, Bahaguna P. Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol 2001; 19:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/37\">",
"      Todeschini G, Secchi S, Morra E, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 2004; 90:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/38\">",
"      Zinzani PL, Martelli M, Bertini M, et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica 2002; 87:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/39\">",
"      Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 2006; 17:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/40\">",
"      Kuruvilla J, Pintilie M, Tsang R, et al. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma 2008; 49:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/41\">",
"      Kirn D, Mauch P, Shaffer K, et al. Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients. J Clin Oncol 1993; 11:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/42\">",
"      Sehn LH, Antin JH, Shulman LN, et al. Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood 1998; 91:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/43\">",
"      Hamlin PA, Portlock CS, Straus DJ, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol 2005; 130:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/44\">",
"      De Sanctis V, Finolezzi E, Osti MF, et al. MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma. Int J Radiat Oncol Biol Phys 2008; 72:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/45\">",
"      Todeschini G, Ambrosetti A, Meneghini V, et al. Mediastinal large-B-cell lymphoma with sclerosis: a clinical study of 21 patients. J Clin Oncol 1990; 8:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/46\">",
"      Haioun C, Gaulard P, Roudot-Thoraval F, et al. Mediastinal diffuse large-cell lymphoma with sclerosis: a condition with a poor prognosis. Am J Clin Oncol 1989; 12:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/47\">",
"      Zinzani PL, Martelli M, Bendandi M, et al. Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy. Haematologica 2001; 86:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/48\">",
"      Pfreundschuh M, Kuhnt E, Tr&uuml;mper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011; 12:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/49\">",
"      Rieger M, Osterborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol 2011; 22:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/50\">",
"      Moskowitz C, Hamlin PA, Maragulia J, et al. Sequential Dose-Dense RCHOP Followed by ICE Consolidation (MSKCC protocol 01&ndash;142) without Radiotherapy for Patients with Primary Mediastinal Large B Cell Lymphoma (abstract 420). Blood 2010; 116:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/51\">",
"      Dunleavy K, Pittalugal S, Janik J, et al. The addition of rituximab to dose-adjusted (DA)-EPOCH obviates the need for radiation in the treatment of primary mediastinal large B-cell lymphoma (PMBL): A prospective study of 58 patients (abstract 043). Ann Oncol 2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/52\">",
"      Mazzarotto R, Boso C, Vianello F, et al. Primary mediastinal large B-cell lymphoma: results of intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy on 53 patients. A single institution experience. Int J Radiat Oncol Biol Phys 2007; 68:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/53\">",
"      Hasselblom S, Ridell B, Wedel H, et al. Testicular lymphoma--a retrospective, population-based, clinical and immunohistochemical study. Acta Oncol 2004; 43:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/54\">",
"      Gundrum JD, Mathiason MA, Moore DB, Go RS. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. J Clin Oncol 2009; 27:5227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/55\">",
"      Zucca E, Conconi A, Mughal TI, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 2003; 21:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/56\">",
"      Takahashi H, Tomita N, Yokoyama M, et al. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era. Cancer 2012; 118:4166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/57\">",
"      Connors JM, Klimo P, Voss N, et al. Testicular lymphoma: improved outcome with early brief chemotherapy. J Clin Oncol 1988; 6:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/58\">",
"      Tondini C, Ferreri AJ, Siracusano L, et al. Diffuse large-cell lymphoma of the testis. J Clin Oncol 1999; 17:2854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/59\">",
"      Visco C, Medeiros LJ, Mesina OM, et al. Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy? Clin Lymphoma 2001; 2:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/60\">",
"      Avil&eacute;s A, Neri N, Huerta-Guzm&aacute;n J, et al. Testicular lymphoma: organ-specific treatment did not improve outcome. Oncology 2004; 67:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/61\">",
"      Park BB, Kim JG, Sohn SK, et al. Consideration of aggressive therapeutic strategies for primary testicular lymphoma. Am J Hematol 2007; 82:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/62\">",
"      Fonseca R, Habermann TM, Colgan JP, et al. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer 2000; 88:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/63\">",
"      Zouhair A, Weber D, Belkac&eacute;mi Y, et al. Outcome and patterns of failure in testicular lymphoma: a multicenter Rare Cancer Network study. Int J Radiat Oncol Biol Phys 2002; 52:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/64\">",
"      Seymour JF, Solomon B, Wolf MM, et al. Primary large-cell non-Hodgkin's lymphoma of the testis: a retrospective analysis of patterns of failure and prognostic factors. Clin Lymphoma 2001; 2:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/65\">",
"      Vitolo U, Chiappella A, Ferreri AJ, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol 2011; 29:2766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/66\">",
"      Osborne BM, Robboy SJ. Lymphomas or leukemia presenting as ovarian tumors. An analysis of 42 cases. Cancer 1983; 52:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/12/18634/abstract/67\">",
"      Zhao XY, Hong XN, Cao JN, et al. Clinical features and treatment outcomes of 14 cases of primary ovarian non-Hodgkin's lymphoma: a single-center experience. Med Oncol 2011; 28:1559.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16228 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-16712FB15A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_12_18634=[""].join("\n");
var outline_f18_12_18634=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1554322733\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1428162\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1554321610\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1554321906\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93465924\">",
"      Chemotherapy with or without radiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H264593724\">",
"      - Is radiation therapy necessary?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1554321920\">",
"      - Radiation dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1554321927\">",
"      - Radiation field size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93465931\">",
"      Radiation alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1554321934\">",
"      Our general approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1565171255\">",
"      SPECIAL SCENARIOS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1565172628\">",
"      Bulky disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1565171719\">",
"      Unusual sites of involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17320527\">",
"      - Mediastinum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1565171727\">",
"      - CNS involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1565171734\">",
"      - Testicular",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1565171759\">",
"      - Ovarian",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1565171766\">",
"      - Breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1554322479\">",
"      PATIENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1554322733\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/16228\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/16228|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/59/37819\" title=\"table 1\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/21/17757\" title=\"table 2\">",
"      Int prognostic index NHL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/2/22574\" title=\"table 3\">",
"      R-CHOP21 regimen for non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/43/15038\" title=\"table 4\">",
"      Staging ovarian peritoneal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/27/30140\" title=\"table 5\">",
"      NHL treatment response criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36150?source=related_link\">",
"      Breast lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9238?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of primary mediastinal large B-cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=related_link\">",
"      Initial treatment of advanced stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=related_link\">",
"      Management of gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/19/26930?source=related_link\">",
"      Patient information: Diffuse large B-cell lymphoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/60/27588?source=related_link\">",
"      Patient information: Diffuse large B-cell lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=related_link\">",
"      Second malignancies after treatment of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=related_link\">",
"      Secondary involvement of the central nervous system by non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26970?source=related_link\">",
"      Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33178?source=related_link\">",
"      Treatment of relapsed or refractory diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_12_18635="Tendinopathy phases";
var content_f18_12_18635=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tendinosis phases of pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Phase I",
"       </td>",
"       <td>",
"        Mild pain after exercise activity, resolves within 24 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phase II",
"       </td>",
"       <td>",
"        Pain after exercise activity, exceeds 48 hours, resolves with warm-up",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phase III",
"       </td>",
"       <td>",
"        Pain with exercise activity that does not alter activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phase IV",
"       </td>",
"       <td>",
"        Pain with exercise activity that alters activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phase V",
"       </td>",
"       <td>",
"        Pain caused by heavy activities of daily living",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phase VI",
"       </td>",
"       <td>",
"        <p>",
"         Intermittent pain at rest that does not disturb sleep",
"        </p>",
"        <p>",
"         Pain caused by light activities of daily living",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phase VII",
"       </td>",
"       <td>",
"        Constant rest pain (dull aching) and pain that disturbs sleep",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nirschl, RP. Elbow tendinosis/Tennis elbow. Clinics in sports medicine 1992; 11:851. Copyright &copy;1992 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_12_18635=[""].join("\n");
var outline_f18_12_18635=null;
var title_f18_12_18636="Immunosuppressants and skin cancer";
var content_f18_12_18636=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Immunosuppressive agents and nonmelanoma skin cancer risk",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk of NMSC",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dermatological side effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic glucocorticoids",
"       </td>",
"       <td>",
"        Inhibit antigen presentation, induce lymphocyte toxicity, alter cytokine production",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        Acne, striae, skin fragility, ecchymosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azathioprine",
"       </td>",
"       <td>",
"        Inhibits purine synthesis",
"       </td>",
"       <td>",
"        ++++",
"       </td>",
"       <td>",
"        Hypersensitivity reaction including urticaria, maculopapular and vasculitic eruptions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycophenolate mofetil",
"       </td>",
"       <td>",
"        Inhibits guanine nucleotide synthesis",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        Non-specific rash",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclosporine",
"       </td>",
"       <td>",
"        <p>",
"         Calcineurin inhibitor",
"        </p>",
"        <p>",
"         Decreases T cell activation and IL-2 production",
"        </p>",
"       </td>",
"       <td>",
"        ++++",
"       </td>",
"       <td>",
"        Hirsutism, sebaceous hyperplasia, gingival hyperplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tacrolimus",
"       </td>",
"       <td>",
"        Calcineurin inhibitor",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        Alopecia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sirolimus",
"       </td>",
"       <td>",
"        <p>",
"         Inhibits mammalian target of rapamycin",
"        </p>",
"        <p>",
"         Abrogates IL-2 signal transduction",
"        </p>",
"       </td>",
"       <td>",
"        + (Anti-carcinogenic effect in limited studies)",
"       </td>",
"       <td>",
"        Impaired wound healing, acne/folliculitis, edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Everolimus",
"       </td>",
"       <td>",
"        <p>",
"         Inhibits mammalian target of rapamycin",
"        </p>",
"        <p>",
"         Abrogates IL-2 signal transduction",
"        </p>",
"       </td>",
"       <td>",
"        + (No long term data but probably similar to sirolimus)",
"       </td>",
"       <td>",
"        Mouth ulcers, stomatitis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original table modified for this publication. From: Rigel DS, Robinson JK, Ross MI, et al (Eds). Cancer of the Skin, 2nd Edition. Philadelphia: Elsevier, 2011. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_12_18636=[""].join("\n");
var outline_f18_12_18636=null;
var title_f18_12_18637="Osteocalcin changes pregnancy";
var content_f18_12_18637=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Changes in serum concentrations of osteocalcin in non-pregnant (NP) and pregnant women (P1: first trimester; P2: second trimester; P3: third trimester), at term and 6 weeks postpartum (PP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 319px; height: 228px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Points shown represent means &plusmn; SD. The shaded area represents the reference range obtained in non-pregnant women (n = 280).",
"    <div class=\"footnotes\">",
"     * Denotes statistical significance as described in the text.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ardawi MS, Nasrat HA, BA'Aqueel HS. Calcium-regulating hormones and parathyroid hormone-related peptide in normal human pregnancy and postpartum: a longitudinal study. Eur J Endocrinol 1997; 137:402. Copyright &copy; 1997 Society for the European Journal of Endocrinology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_12_18637=[""].join("\n");
var outline_f18_12_18637=null;
var title_f18_12_18638="Management of hypothermia";
var content_f18_12_18638=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    Sequential approach to the management of hypothermia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 377px; background-image: url(data:image/gif;base64,R0lGODlh2wF5AcQAAP///4CAgEBAQMDAwAAAAODg4PDw8DAwMNDQ0KCgoGBgYFBQULCwsCAgIHBwcJCQkBAQEAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADbAXkBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiotqAY6PkJGSk5SVlpeYmZqbnJiMn6AEnaOkpaanqJIEoKyKq61Br7CzgrK0PLa3unq5uze9vsFywMIyxMXIasfJLcvMz2LO0CjS09Za1dcj2drdUtza4N7jTOLW5uTpRujQ7OrvQO7M8vD1OvTI+Pb7NL0IjgxYJEhAwgACAAMBDLBRoMAPBA5yCCjRsIY+fhhf5GJwgAEDBQEAOEIxcgREkSEn/9ZI6GOAyhkCFgLIxXLGxYw4VeSKOcIAAAECAhQYsECAAp8BFCgQcLAAwZEhEzxaiKBoQBJEjfocsDABggcDQiL0maDh0gUIDIgV6bPEgAMBBBAUWUCogaViEwANWaAByJkMjIrgipDBggUO1QpwMPfEzZyQS+QKcMDrCKUDDDp8oEDkAoMQFE4cuQoBVwgMChwoYICnyc2dRwpoEMBlZggEVxU4iKABgAML354Y0IB1g4MEgqpe6CBkZgALEhg4AHYmwegofzowwBlAc4QvTTyOTL5XAgUHIBwsyX3BgdFiY7rMLuvvg6Bx1wJo/z67a0dSoaXSeQKsch4ACjSGlf9KpInQmyNLAVDXbCnJ9ApUFYoGAARbhScZeSDek4Je2f32gAHzlSQffDOJQKJICnA1gEMjUIcii64R9ZlcITmggEOvqBfacAyG9MpbMiLQV0CyWSgChj8FN9GRHpIwXog40dRWdwFENBNZLBoQWopGAoDAAW0R19ZB24Dpn0y/dfYAcD8FVMCFtD3Z1mAqHYCcCGKyadoBIvwlwFUXhtSkhnQG5iKb22ApaT8lPNCAAAccJeF7CCRwaYQBXNqRhg3OBhRBCbw36gieGoUjnNjd6eClDrxyp0+9uQUBpmLJciavCL63QEgcTfmkohnOd+ZhKkFAY6STRqvRGwcC8MD/A0+0dWBV4knrLQtXRlGcnk+0KoBPDMAJ7bfsdptRuO2SA+8s88bbTb0ynJRCRTBUWYJBUeBr7zlUzDeigs0Q6aCXTwg8cDtF6BWUi4Yhtl9cRf271HaEeVVdXAqYJlOvEp61Hm0zEqRYAFt95NoQDj88TxHPYbcYd51992KNBDHwT0oo+2gmAyW9ohtvvqU643x/JSWSALv5RkTMMudTxIR58jQfhxqaROgIi264Z9EivELgKgZvPUJoZE9dNbsCL/mmhlQuSELYtrS9io9Adj2fLKu0DfPb3wosHILJTtRoeGImVleGP831VUSytniohGh/Pd8CARFVosNUE+6L/8PoCTBslBouGyEJxUIdNgJAHWoArUabSbsIpyob+3okuy16tKG78jvwWQ4/afCJIG98K8of0vzynzxfiPTQC/9u9SBSP4j22BvCfSDfd7998eLnFP4f55ePPvnqY5R+H++3v0f888vvPvv21yNKKvz37///m6Bf/uwAwAJmYi8GTKAlBshAHZSkgRD0wwMjSME8TLCCGKTDBTPIwTdssIMgbIR+QkhCNHywhCgMwwlTyEIurJAGCoyhDGc4iWRIhYY4zKH/nsWDF9pEh0AMYikEOAajCPGISKREA9S1Ax8agx9EFMPL1DHFJo4QB1GkQxbBUEVydDEHTozBFoeRjP8vesOMNwgjDMYYBzZ2AY3agGMN1DitfbiRC3K0Rh5nQEcX3NENf9TCHqExyBj0MWF2LCMTvbhIMF7xF1BUZD0KCYNDgiuSyKCkJH1gyRUEkg2fxIImM9lIHHRSJ5gsxihVWco0PtIGoVTGJt+xShacMgXZIFoAIIWDiejrX7z85QwcwMscpAWLs2SBAaTyAB6+4JgjIKYPanIDYbbAXyio5QpuSY1rxigwrTyBGdHmL2EajAbaRIE0IUlKF6imNp4aJi/TSZJHHvKcfnwBPevZA2l0pydOCUu6BsMk0ynJLz0CCqI0tDKfOOVipvNQAZYyF4+pS0dLLJlcKHaYrRT/RVMDcBkCAtMZhDgkACQFFF4QyUoXYAdQEGWZQlw2MoOaVCGHyWhVLkcXobDOpk6JC7Y0OrGJbvQnyuHKQLKiqaeFzCVCdZBVROAAhZZNn+Gc4ystwgKejmAAEBiWo+r0gAUMbTrVCcjs+sY0RXVmPjrz0BINYDOUjUA1rKHTXG0WkbKaCTZP2w1uoEMQnhDgOgSh03c8mUyd7KlQbg1srvw60ijhdTozWk1rFpIcn4rAMAboC4rmOi46/WWvBMGMWiDAGCVZK2edGSlxMlOcy/JErePixj5PwE3HdJWJ56xt0irDphxVFQKc1dCQNqTcDpEAdoMxaxUf4KWYQBen/6hrEX9Y1KK5JepBScGmlRqLSxMsl20kS5VlokRd3A3gPo6YWC8WAJJQcUUl1v2aI67ruZKwp6z94Rqf3Avf/CjkuMl1wW5N0Ft3qUABQ/3qSzjjgKEOwAFZWwhHDmJYukXqbwOW8ICrqKL7jthJNiLTVb17LCRxpZi+bWcLjvOhq7btwhkucVJk1LcSCAAsXLmRew3miLRxtyQpNpaIo7RjrhRgw6jTbVZhuFVKrYA4NBqAaV4yuwbgCl0TuVyX9kMnckKnc2adz+JKwLUAYKuKY6VTm9+sYbMSwE1tW1SiAuWgS8rYlp8RAbY4h12yHdNRMYkzV7zc514EwKz7Gf8Kfm/jk+/MWSReKpqbjrrlITPaTGPGbHevOWU+VtkmLWgdYvCpAC8Vy08AKNZ0TFfm1O0udQegr4c4kimfdNEBmWrUAXr9k/cwBSGf4m6ionwsM6nq1KMWRiEpA5TY3ppsr+Ywc4LdFVUFBBjAxpSk3YuQXJ+O15pSDVNK0qoIwU6hBuNJqjDFgFm7J8Gk/kGDa3yDcRWx1LEg7zgWXIJ9j/cG1fq3E2JpBYLDwuFgg7YYUyltgD/DiAVEoP8YjgaOUwHirMA4ADXeP4fFBWEoQFGQASWjN3h8CiB/5mNbYM0UACwLMTf4uoKQALPOHAXEcURGgw7snwNB56j8sxL/1unjUuIzxjX/uMUrKfE1EmEvQznMyOryLCI7RyWL/axVyyIhggT1qChdjAiMWtGvuEQ5g1N6Esie9s70pWmDCQ5cNmpUtChEFGVRWX4cKpUfOyHnVa+jEDDTm4bkFu6DAU5gHGIwCJvEyw/V2kSIkxYaEyAgC8AWan+CMtXGvaVMMCxi0ZrgkWB5dkpCGua03FYYKYS0zkQC4vtJhJE8QCxujvZgaGPgoKNnTwWAQHVQNx+vd9cl/JXuyBIPS4EbocNz667ri4SQpdROuWvrWswVPPUXIF34+kZWs3thMANkTssmqEt/NN+1BonGyNk9fzflrvvWQ27ZXsc33VU3/4AjfuXHA7uHC70XEmeCO3/iFiqRK0+3domxCoRGIgYDa69QYWIjEnT2JAwjBC8nBeOXb8vGU1zzFxkIO3ZiNM5FaJ4Tbwe4Awm4AwLjX8PWO1ixK5hyEBO4KZhCEMThKgqxK3BRNpiiKejmazKhbjDGe/x3BNg3EsViLZdyOmAFLL2xGBdyAA6gO0Dhg5PWBDUoInDwdO8zglFQgotQhjmghhDIb1MAh0/AhorghsiUSFF4RjNoS9THUvpjfd2Ah+xkD3R4eH0YDIRYfXqIerSUiCpwfocIBpOYepC4C4vIVY1YcZN0ifykgJuoiJ54C5loZYYoiHE0igz2h352iv97OIiqWHCsyFih6At2mAiliGq1iImx+HC9GHFQ6IqOSEW/2Gy4kETImIyOUIlLIHLK+Iw4lFGcNIuRCI3WCEQ2dI3aKEO550gt9I1goH/gOI7TSI7miAXieI7qqFXr2I5QkI7uGI9+KI/0iATwWI/4CIz5uI/px4/+2EPU+I8CeTcBOZADeY8GuY4ImZDnuJAMSY4O+ZDacEPb2AkkV5Ga0I0SWQfOiJEeCUDSuJF5cIutQJIiWQUmCQopeZIkWIy8yJJ4sJKMIJMwiYiQQZM1aYk36ZI52XA8SYo/2ZMwF5SzgJNC2X87eZRyYJSIwJRKeXVE6YtPCQdTpHJPeHP/d6WRUoCVSMAvMeCUUxkEUzRRDYByZhIR7GaWYLkwS5AQlLSWYekDVZQ2NFV2SCUUHbMXEoJQZjJVWDEACREYfkd28OdkJvMkXJcAFaMY2PJQIbUUMqEjnmUCitlRUYVTCyATlWkxTsaXbPcoy0ducckGc8kgUCOBE6FarucT0cF6tqUuAcBalRlaXiYbnRETu2E7SCgUNzMntDVucRE1m5JXpdSbwLFWfeF4DtGbscEy1LEQo0ch6gKXo0mDwMV9LaJi2YE1GVJgE6OP9CV09zVRhDIkZ7NizDdp2rkK7ZVdJkB/7AV8H6hiPBF97jkC1FmdEnGdxmhm/iUUDcAk/xnSZDNCkLgDZM+hfAzgAI4igN+XnkOmbCViRvAZE/8JoYuCf12Un/p5A6XZn6SSabXxNYbSOZ/GS/4FaaEFHb50hJdTObJQoSaGbX2yEAUQYeQmgw34E9pGKilxFZe2oVHZoUUwRWfCWp+jIU44EqVzbv0xb6tijN6hKoAFADp1O6Mmo+tJVZmSUf+En1JCbpRxhBhKLP2xhPcpmkRqBhyKBG0xLn5Xh0O6pkLQpkcgKnMRgmQ4p3QKBHbqB3/ap+SXlIKqcDkRqIW6AohqSAXZkokqRXy6TUaRFoNXdmHRl16FO8pxF9+5mYz5JIGhp3v6qGEAl0IzUk3zVmElFP+aNUWqpVgpsR2+uVaAAR04Oqqk+gVwKWDMJQJjohLeqR8jAV4RIqPPJ15ImateAJe2UIBEFiNOZqAuBn/GWjdQsKjKSgJwyWkwmGYqoSZ9BjYRwWdmAqHM5h23qpPZikeRmgLvdijvKoas4m0k4IS/4qJhGmVJaHRKgK3rmqZ5kD7+uq4DG3BS969bULB2oLC5yrB04LCPCrFL2a4I+5UUe4cXW7GDeqgZq7G/Ragei5IdewgSW6glS5UjG7LZlLKFcLJ96rJuALNrKrOkybIq23Qge7NraLODQLMd2pEfGbSpEJI6CwUUKbSWcJFIOwlaWbS3EJFO2y5QG7XfMrX/VCstVnu1k5K1WoslXNu1IPK1YBsZYju2OVG2ZpsRaJu2/LC2bGsPbvu28BC3cqsOdFu35HC3eOsNeru32tC3fmsNgBu40DC4hMsMhnu4yJC4iisMjNu4vvC4kKsLkju5tFC5lgsLmJu5rLC5nIsDj7O0pKC0oosJZmm5QVe6qhtDq/O5ITYwP4i6yBotsTu5tSstt9u4uTspu3u4vYslvxu4wQsiw7u3xRsZx1u3yZsTy/u2zZsRz5u20csP0zu21WsP19u12QsP23u13asO3xu14UsO41u05esN53uz6asN6xuy7WsN76ux8QsN84uw5zQUBcoqp2tzbHJyEsEF/wlRfolYv/96Tm8HmxJnMCfRc/vxhrIoA+UrGyw1uypAwOuKTyVhVN8JMi0DmSKBMpkXFMsXUljxUR3sGnqhADuRVIDZM0B1mKFSGwWxMaFFUQS1FCMlGIXRUdkhFoIZEFV1OQMAeCLhIkbhEGc3VIHhVRacrRgsFqbVI8QyGqc5XEuTmjHyIpnqWlxSxbH2GZVzGTGyWowBWqKVm7miNDxUGbHWG5mBHcGJAIPFV9ZiVg3CEaHVM/tRWwQAfwbyGcRxe7/ZG3m8ZK7bNc22oyMBAY8QOCSDfyUhXP8CYBJKaMJ3odBRXxl1nk+3o2byrXbcO3hDH2eGFQg2ahYoE/9MIYPJF5qI7LpPXH9GIiMLQTaQLBYUdqtJlqSuMRnAFx8IagAO+sqIfMsrNsqlAidQhn2Wo8omhjry9xJNrKyxLCaVlhJDxTtXdTja2WUzd2fgkaTf4X4FJ6JPoqIF8KKZ8y/OEmmXlmcZYhik7DSgNq5l1hbsOa6+wcoVaMiw/BKeUpbldhghQVfDFsorljvchSCi2m4S2hpBkQtLuhbhthpbWCuaqiCt82TDpinwXGxhSMp38R7OSWu17IXahR6jwsqq0hjTnKvv629rAJYvTartm3AznbI1/ag7vQs9Xag/fQtB3adDPQtFvaZH3QpJ3aFLDQpNXZ1PzQhRHZf/U60IVT2VV40IWa2UW20IXS2UX00IYZ2TYy0IZQ2TZw0IaX2Sa+0Hbb2Rb80Hcf2Qc60HdZ2Qd40HeT2Qe20Hff2Pf00Hgc2Pqbu6hg1Areu6oXvYmbA/jG0J+3vILifZosOMlH0Hln3ZdZDZmj0HnN3ZbQTaD/PZog1IpW0vpH3aa5Daqp0GrN3aZ/DasF0Gsj3bY1Dbth0GuJ3bX7DbvN0Fvv3bWxDcwp0FxF3cV3DcyF0Fyu3Ejw1Ejv3c28iz5ZMf0n3d2D0K35mQnls93T0w37084R0v4z085c0u5y066e0t6/027R0t7y0z8S0p8w3ejTqO9W0v+R22902P//tNHv+N3v39jQFetQPeQgXO3gfOQgmOtQueQg0O3w+OQhG+tROu1Nl9CaSb4RduAxzOPxv+4ZxwBNYt4iZeCekT3Se+4jRENRW+2cwNji7e4YFIBc1tPUXw4loU498448OT4jJO4jQOD0De40L+4zzeQj7+O0Wu5EfO5EnOQkte2VGeQlNOOE0u5U9O5TYe5Eag455d5Sh05W+T5TMgMvDXA1zpA2tOTSrAdDUA50AQdVb35UP+DmYuAxgX2RN3li2QvCeByR8rDwsWu9FL5lWT5xZLAimMxAlwqXdVeHlqVUMcAIH3JFoxUx4cw5mxFE31JC5CFg1RWMrRJR7M6P96GSWVThA7dRVCYRcrhZlEe3ZecRg0wsGazhOc3nfyyog5fufqoOj9AmTLBMj7vKpYcRywF2t73BB93Gnf4ShxbMUFEHptrK23kRsaoppejBWsWVgz8uyvORPKAauXRSdfRVos0x3RTsXCqcZovM8UTIu/juRdbgMYV+2q3GlxmB0XJgDIdawb0shJWnmc40wA8mjQpZ2Cs3ZxkWHdFazdRaw/Vl0XNYZbQ/C2DNDeR8xPZOcscKOWzq8qwJV03gPQZBIkHwNUoadZteYq4JX5dO818DKusSIm4HXLnGB/Q8sFz/EB/1UdxSM+CqJ3FaAsBiM89nzA8WIlZjcQ2sf/LbfxVPUj2TnvSVfvKsARj/5o+RKC7Svncr7oP0HM2PQKJ0+ZfO5g3+ChcNJes+PxKxhq96whhleutqw5VDVCmWItdJIi5hxth2MonLUVJ9pd5JrDIoDuIUZ/d6/N2fk16uzxfa71KdDOMKUjmlkxDrFTfCF4ESV2fhdQI4Trj8kUKSUSoeoiJ5WYnV8UOMrrZRdVd6coCrF3c5EXR/x3lv5QTpUWnv5YHcP59N72+A4nI73SVZKFR2hvdEIZXzgRBp1rSYpUUmFsMxcrdTPR6FkowjKgKA2l3+Y1wAJs6HHxOSr97kH9bXMqF21mvr6AFfw1R6+c2oEzG5IW2AJX/1EBAgLALEbRGAO0BIALOC0jBkKBQAmw6ASzPwCCAYAgCBSGJ4Qh+LoBEA3AoDEwNAqGw4NIoGaxiCIgUaoCCoQBYiByKKKkIGP8CrQEjmb85X99/QkOEhYaDgYeKi76uTE+QkZKTlJWWiZaMuIZOvo9tAAEBA1RiTQ4XJUCQBioLijgWXX6QeAFfG2ShbYEOpImDj04ECYoCHx1kpKSdW5+LRAJjfWKsL4oLDAU/G2SzhJiZoq7hI8rfpunq6+zS5a3u+QSFkBwg3YTOTYtsDpSC3UZcAVdEYECd5GLx8uFLy8vhsjzA2cbMhFCiCyrqJDMsl8MRYQrBiHaRm8WC/+9g8copcqWLl/CzMSSXcRBR1wYSIDggAsBY0xScXFAoIihI2gswFmAoAAnY3IFcubCwSiHPQVOieJHwA81qi4K+cHM4oFpAIQBwEKulS8dUaLF8IPvK8qYj2bazat3b0u86moKMqDggICmoQ4cAAV0AeJhjna+suiA8IGlJ18YYHwgKdSNRg4oaOXx6mEBSV9I0aMRLAPCzCAISJxQMGKxAQ6gEoGgMNfbhVvdyZPvMiK+hvwaV1Rg24sEbhWlYGPADkNCCIb5YQJpuSUTfhIEIDkgwHN2yM0BTi5TPXs/5+0iXyZIfl7nckEpV9BAh7URpz8CKBF1i9hHiRv4BaD/wABGLTgALPC8J0567U0SIYUQXggIITUsgMAJDyZQWAsfIuFWAtsgsMBNhMyQDRULQBPPDH3MwBUVRBRgzIo1hHZjgQEq4FaQcjUQ3oGGlbGcMR3KqIdg3hCRAAkLMNfigNysCEBlZQzjgA4F8NQIA8YgMCNDMCIRD3OCWGjJhBnCGSc4cb7zQFJlbtEFFa3wkCdRpEHAhBOCtGbCiVmcQJEOPEhhKEJGPRjXDKFA4GUjFpHgQn8uJDDUUlZgsY0SY0hBzqJUltrNHg/EQYIJKBQizz8ZYXlDDjucWNkW0awxZ0xvyhmsnG269E6nOpGWRg1FgpUMEaekMoiLLnwS/08QUSEBgZ677LRRLXjggt8Ls7CS6aUBKhOlMYFgm9BcjrwSC0mCyAogrfcltAtaYB1CLCXAimMfd4wMrM6855hTMEz+qpTSAA4wS8oJP7xrESn7bLoVSblIhVABvu3SDC8GEQHYLEEOee5X6U6kS7tkVAyQQcANIk89L+4Qzc3B5WuLYgcX96u4NLXwo8aCGG0OcQH+sTQkuSS94dCUMIyhINpNauOCLjxoY7e7BqVlyTSH0gcC3UqjCx7cGRCuAdbEheRTU8/SWsZUhOnsRTZ6pTYo4TaLlFJlXImQCy5SddYw5vLs96Ric1p4vjABvOEM2D0JSo4i3lgG5ySG8v/xUkSkiGRgNVh6FJMFJDBeKGks+VSRA7DuOigtisXplGyp2KOIo6dlDChSwijqETeoOPUiVbfzTmuxjfE8AIOZJoNrjDFGhGbDlOoHbTfdJpvfYMamwyadopmWZpwNvVOlLzTQR9MCtG4xRmw0oFrPfyMEFAyUbQMCa+pJA/Lngp38Ji2FKYs99vc//ehsgO6xS+UQ8YMFBMEocYFUCzaRij5xwQvHW1sDBEWIuITIP69KwQoWAoVSdYp2KmABGQrFuq0Mw05R2AarpqcgA2xCg3lYVRwU8MNANaFCdIrJAwYlrAulKCbAyUIU/sMmCipPEdSQAh7IFKZNbOJjAoj/GK+Cs69CWANesAiALE4SiGIc4yuzeEbujkaGfbiGYwHgYoJEAJRcQItsd1ki5QT5RPYwAGjwyN8B3JLIughNiaVokEDaYBEwIqEBFBPO5HzWL3sFZCBuhIECKCLHUdLnIWXkQgpocI/wDKWSgTMcxgypRUIeMpe6TAfznpbFT8LgAW+zAxPg1kFYci0PYkkEHtCglQI4EXKTCsBpTDDHsKQBGXkbZYIOeLRMEaAVKQwAdvAwTG/+ETvRMEokerkOd+4ynoeE5yIqyKbY9AiBskEfDTdBPRpKj5kdJExSepidzahoKgC8ZmocEIjC1E9D3xNXbAozhgTkzxhpIAwC/zahT046gnwpaowkM+QXp9klJwHInc8kaA4HSA4e4FEkeOr4hE9IbqbvxGJJ7cIk73FKfjBJpUlxCclbsqOJByLHzNpBVHgkqEFNCw8N/+AlBliBGwpipznoqQh7/sGrjMDOd/InAFuq5KkUEqs4WBIiBQSidD9ggFjoOgACkKd2LRgAjKJRox9k7hwWcasAHqQsepnJcyvyRl9HUNcfvJU5Ky0sToRXiC0lgKxroQu9hoZZzYbick+Kxlt/ydZY/VKeqn3JaS/BohJ4BUxaGAIWsGKCNbShhYlKVKNuKMRDdLMIpjmYq/p2VzYtSgcf1IESEBUGWaDADCnICgGSC/+5uAQNHWwshk23Uh5doKO6O0DVFIrLktbWLLWrXW/zjOqHaX3hAUeoQQukwEDwWqRaoXgAPfTER40WolEu2EYVBgjf42xEjGTUryii0AAGxiht2PovSv8hkSY2UrHPSWFYmeZAMhzYV5RTL3tL3FX3qtJdChIIc1yTL5El2DeUZEOASzifed3LVyTc5EX0KBT7kQZbM47pzfh6UJzs7DsHMGSRrei3hOT4ipE0MZWtVtRBxKVtYADOGBzgZeyE8yto8wnbwhkob0LzD1KgDtsylmVmClLIYeoaG8LkExh8WXFpoa5CzvnMaCLOCUigRyu6p2SafexwP0jcBA33hTf/H/UlYK0ypVeCYpyI6I2UYUCn0pLh2+TmDogZEWV08NGzCFUIZhUB+TLsvcI49IBZabQ/CcrJ8BWNJ1tIAG0OsMyNnNqgqCHMWZlaBmIXjgDEdkxciR3njdwR1uflaaWr3dZLJ+enkwDOCagVTfVoG07cnrWUR2ztc1cCvVSDE2gjkZr7BgCtfGk3FBkZU12YG936hoS6e7rvf/Ol3/gCOMFFfCGBFzzhGpqywhWOcH43POINo7bECf7wQVY84ydmuMb1fXFLdzzk6+a4yKv98eWVPOUYz7fKK31ypLY85kFjucxN/HJg1jzn+JY0iXX+xJsj2Oc1v/ikhX7loxtdouVE73nS4QT0SDdd5EuPujyfbnCqd3zqWNel1We+dY1r/es/x7bYE070+fos7WpfO9vb7va3wz3ucp873etu97R3nU133zvf++73vwM+8IG/+HgEb/jDIz7xho+T4hvv+MdDPvJMLzvlK2/5y2M+85rfPOc77/nPgz70oh896Utv+tOjPvWqXz3rW+/618M+9rKfPe1rb/vb4z73ut897w0RAgA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Lanken, PN, Manaker, S, Hanson, CW III (Eds), The Intensive Care Unit Manual, WB Saunders, Florida (in press).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_12_18638=[""].join("\n");
var outline_f18_12_18638=null;
var title_f18_12_18639="Perforated duodenal ulcer on fluoroscopy";
var content_f18_12_18639=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F78491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F78491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perforated duodenal ulcer on fluoroscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 283px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This&nbsp;upper gastrointestinal series was performed in a 42-year-old woman with a known duodenal ulcer. It&nbsp;demontrates free air in the peritoneal cavity (thin arrow) with spillage of barium (thick arrow) out of the duodenum (D) due to a perforated ulcer, which&nbsp;was surgically repaired.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_12_18639=[""].join("\n");
var outline_f18_12_18639=null;
